

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/185, 31/50, 31/395, 31/34	A1	(11) International Publication Number: WO 97/39748 (43) International Publication Date: 30 October 1997 (30.10.97)
(21) International Application Number: PCT/DK97/00167 (22) International Filing Date: 17 April 1997 (17.04.97) (30) Priority Data: 0463/96 19 April 1996 (19.04.96) DK 1436/96 17 December 1996 (17.12.96) DK (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors: ANDERSEN, Henrik, Sune; Kastelsvej 24 st.th., DK-2100 København (DK). MØLLER, Niels, Peter, Hundahl; Midtermolen 4, 3, DK-2100 København (DK). MADSEN, Peter; Ulvejbjerg 7, DK-2880 Bagsværd (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IF, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS (57) Abstract <p>The present invention relates to novel organic compounds, to methods for their preparation, to compositions containing them, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phospho-tyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in <i>in vitro</i> systems, micro-organisms, eukaryotic cells, whole animals and human beings. The novel organic compounds are compounds of general formula (I) wherein (L)_n, n, Ar₁ and R₁ are defined as defined in the application.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS

5

Field of the Invention

The present invention relates to novel substituted acrylic acids, to methods for their preparation, to compositions containing them, to their use for treatment of human and
10 animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phospho-tyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in *in vitro* systems, microorganisms, eukaryotic cells, whole animals and human beings.

15

Background of the invention

Phosphorylation of proteins is a fundamental mechanism for regulation of many cellular processes. Although protein phosphorylation at serine and threonine residues
20 is quantitatively dominating in eukaryotic cells, reversible tyrosine phosphorylation seems to play a pivotal role in regulation of cell growth and differentiation as well as in neoplastic transformation (Hunter, *Cell* 80: 225-236 (1995); Schlessinger and Ullrich, *Neuron* 9: 383-391 (1992); Cantley *et al.*, *Cell* 64: 281-302 (1991); Ullrich and Schlessinger, *Cell* 61 :203-212 (1990); Hunter, *Curr. Opin. Cell. Biol.* 1: 1168-1181
25 (1989)); Hunter and Cooper, *Annu. Rev. Biochem.* 54: 897-930 (1985)).

The regulation of protein tyrosine phosphorylation *in vivo* is mediated by the opposing actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPases). The level of protein tyrosine phosphorylation of cellular proteins is
30 determined by the balanced activities of PTKs and PTPase (Hunter, 1995, *supra*).

PTPases - an overview

The protein phosphatases are composed of at least two separate and distinct families (Hunter, T., *Cell* 58: 1013-1016 (1989)) the protein serine/threonine phosphatases and
5 the PTPases.

The PTPases are a family of enzymes that can be classified into two groups: a) intracellular or nontransmembrane PTPases and b) receptor-type or transmembrane PTPases.

10

Intracellular PTPases: All known intracellular type PTPases contain a single conserved catalytic phosphatase domain consisting of 220-240 amino acid residues. The regions outside the PTPase domains are believed to play important roles in localizing the intracellular PTPases subcellularly (Mauro, L.J. and Dixon, J.E. *TIBS* 19:
15 151-155 (1994)). The first intracellular PTPase to be purified and characterized was **PTP1B** which was isolated from human placenta (Tonks *et al.*, *J. Biol. Chem.* 263: 6722-6730 (1988)). Shortly after, PTP1B was cloned (Charbonneau *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 5252-5256 (1989); Chernoff *et al.*, *Proc. Natl. Acad. Sci. USA* 87: 2735-2789 (1989)). Other examples of intracellular PTPases include (1) **T-cell**
20 **PTPase** (Cool *et al.* *Proc. Natl. Acad. Sci. USA* 86: 5257-5261 (1989)), (2) **rat brain PTPase** (Guan *et al.*, *Proc. Natl. Acad. Sci. USA* 87:1501-1502 (1990)), (3) neuronal phosphatase **STEP** (Lombroso *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 7242-7246 (1991)), (4) ezrin-domain containing PTPases: **PTPMEG1** (Guet *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 5867-57871 (1991)), **PTPH1** Yang and Tonks, *Proc. Natl. Acad. Sci.*
25 *USA* 88: 5949-5953 (1991), **PTPD1** and **PTPD2** (Møller *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 7477-7481 (1994)), **FAP-1/BAS** (Sato *et al.*, *Science* 268: 411-415 (1995); Banville *et al.*, *J. Biol. Chem.* 269: 22320-22327 (1994); Maekawa *et al.*, *FEBS Letters* 337: 200-206 (1994)), and SH2 domain containing PTPases: **PTP1C/SH-PTP1** (Plutsky *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 1123-1127 (1992); Shen *et al.*, *Nature*
30 *Lond.* 352: 736-739 (1991)) and **PTP1D/Syp/SH-PTP2** (Vogel *et al.*, *Science* 259: 1611-1614 (1993); Feng *et al.*, *Science* 259: 1607-1611 (1993); Bastein *et al.*, *Biochem. Biophys. Res. Comm.* 196: 124-133 (1993)).

Low molecular weight phosphotyrosine-protein phosphatase (**LMW-PTPase**) shows very little sequence identity to the intracellular PTPases described above. However, this enzyme belongs to the PTPase family due to the following characteristics: (i) it possesses the PTPase active site motif: Cys-Xxx-Xxx-Xxx-Xxx-Arg (Cirri *et al.*,
5 *Eur. J. Biochem.* 214: 647-657 (1993)); (ii) this Cys residue forms a phospho-intermediate during the catalytic reaction similar to the situation with 'classical' PTPases (Cirri *et al.*, *supra*; Chiarugi *et al.*, *FEBS Lett.* 310: 9-12 (1992)); (iii) the overall folding of the molecule shows a surprising degree of similarity to that of PTP1B and *Yersinia* PTP (Su *et al.*, *Nature* 370: 575-578 (1994)).

10

Receptor-type PTPases consist of a) a putative ligand-binding extracellular domain, b) a transmembrane segment, and c) an intracellular catalytic region. The structures and sizes of the putative ligand-binding extracellular domains of receptor-type PTPases are quite divergent. In contrast, the intracellular catalytic regions of receptor-type
15 PTPases are very homologous to each other and to the intracellular PTPases. Most receptor-type PTPases have two tandemly duplicated catalytic PTPase domains.

The first receptor-type PTPases to be identified were (1) **CD45/LCA** (Ralph, S.J., *EMBO J.* 6: 1251-1257 (1987)) and (2) **LAR** (Streuli *et al.*, *J. Exp. Med.* 168: 1523-
20 1530 (1988)) that were recognized to belong to this class of enzymes based on homology to PTP1B (Charbonneau *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 5252-5256 (1989)). CD45 is a family of high molecular weight glycoproteins and is one of the most abundant leukocyte cell surface glycoproteins and appears to be exclusively expressed upon cells of the hematopoietic system (Trowbridge and Thomas, *Ann.*
25 *Rev. Immunol.* 12: 85-116 (1994)).

The identification of CD45 and LAR as members of the PTPase family was quickly followed by identification and cloning of several different members of the receptor-type PTPase group. Thus, 5 different PTPases, (3) **PTP α** , (4) **PTP β** , (5) **PTP δ** , (6) **PTP ϵ** ,
30 and (7) **PTP ζ** , were identified in one early study (Krueger *et al.*, *EMBO J.* 9: 3241-3252 (1990)). Other examples of receptor-type PTPases include (8) **PTP γ** (Bamea *et al.*, *Mol. Cell. Biol.* 13: 1497-1506 (1995)) which, like **PTP ζ** (Krueger and Saito, *Proc. Natl. Acad. Sci. USA* 89: 7417-7421 (1992)) contains a carbonic anhydrase-like domain in the extracellular region, (9) **PTP μ** (Gebbink *et al.*, *FEBS Letters* 290: 123-

130 (1991), (10) **PTP κ** (Jiang *et al.*, *Mol. Cell. Biol.* 13: 2942-2951 (1993)). Based on structural differences the receptor-type PTPases may be classified into subtypes (Fischer *et al.*, *Science* 253: 401-406 (1991)): (I) CD45; (II) LAR, PTP δ , (11) **PTP α** ; (III) PTP β , (12) **SAP-1** (Matozaki *et al.*, *J. Biol. Chem.* 269: 2075-2081 (1994)), (13) **PTP-U2/GLEPP1** (Seimiya *et al.*, *Oncogene* 10: 1731-1738 (1995); (Thomas *et al.*, *J. Biol. Chem.* 269: 19953-19962 (1994)), and (14) **DEP-1**; (IV) PTP α ,_PTP ϵ . All receptor-type PTPases except Type IV contain two PTPase domains. Novel PTPases are continuously identified, and it is anticipated that more than 500 different species will be found in the human genome, i.e. close to the predicted size of the protein tyrosine kinase superfamily (Hanks and Hunter, *FASEB J.* 9: 576-596 (1995)).

PTPases are the biological counterparts to protein tyrosine kinases (PTKs). Therefore, one important function of PTPases is to control, down-regulate, the activity of PTKs. However, a more complex picture of the function of PTPases now emerges. Several studies have shown that some PTPases may actually act as positive mediators of cellular signaling. As an example, the SH2 domain-containing PTP1D seems to act as a positive mediator in insulin-stimulated Ras activation (Noguchi *et al.*, *Mol. Cell. Biol.* 14: 6674-6682 (1994)) and of growth factor-induced mitogenic signal transduction (Xiao *et al.*, *J. Biol. Chem.* 269: 21244-21248 (1994)), whereas the homologous PTP1C seems to act as a negative regulator of growth factor-stimulated proliferation (Bignon and Siminovitch, *Clin. Immunol. Immunopathol.* 73: 168-179 (1994)). Another example of PTPases as positive regulators has been provided by studies designed to define the activation of the Src-family of tyrosine kinases. In particular, several lines of evidence indicate that CD45 is positively regulating the activation of hematopoietic cells, possibly through dephosphorylation of the C-terminal tyrosine of Fyn and Lck (Chan *et al.*, *Annu. Rev. Immunol.* 12: 555-592 (1994)).

Dual specificity protein tyrosine phosphatases (dsPTPases) define a subclass within the PTPases family that can hydrolyze phosphate from phosphotyrosine as well as from phosphor-serine/threonine. dsPTPases contain the signature sequence of PTPases: His-Cys-Xxx-Xxx-Gly-Xxx-Xxx-Arg. At least three dsPTPases have been shown to dephosphorylate and inactivate extracellular signal-regulated kinase (ERKs)/mitogen-activated protein kinase (MAPK): **MAPK phosphatase** (CL100, 3CH134) (Charles *et al.*, *Proc. Natl. Acad. Sci. USA* 90: 5292-5296 (1993)); **PAC-1**

(Ward *et al.*, *Nature* 367: 651-654 (1994)); **rVH6** (Mourey *et al.*, *J. Biol. Chem.* 271: 3795-3802 (1996)). Transcription of dsPTPases are induced by different stimuli, e.g. oxidative stress or heat shock (Ishibashi *et al.*, *J. Biol. Chem.* 269: 29897-29902 (1994); Keyse and Emslie, *Nature* 359: 644-647 (1992)). Further, they may be
5 involved in regulation of the cell cycle: **cdc25** (Millar and Russell, *Cell* 68: 407-410 (1992)); **KAP** (Hannon *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 1731-1735 (1994)). Interestingly, tyrosine dephosphorylation of cdc2 by a dual specific phosphatase, cdc25, is required for induction of mitosis in yeast (review by Walton and Dixon, *Annu. Rev. Biochem.* 62: 101-120 (1993)).

10

PTPase specificity

Several studies have addressed the question of PTPase specificity using synthetic peptides and provided important insight with respect to primary structural sequence
15 requirements for substrate recognition (Ramachandran *et al.*, *Biochemistry* 31: 4232-4238 (1992); Cho, H. *et al.*, *Biochemistry* 31: 133-138 (1992); Zhang, Z.-Y. *et al.*, *Proc. Natl. Acad. Sci. USA* 90: 4446-4450 (1993); Zhang, Z.-Y. *et al.*, *Biochemistry* 33: 2285-2290 (1994)). However, an obvious limitation of this approach is the lack of defined three-dimensional structure of the peptide analogs. Likewise, the PTPases utilized for
20 these analyses are removed from their natural environment. Since at least part of the PTPase specificity seems to be conveyed by a defined subcellular localization (Mauro and Dixon, *TIBS* 19: 151-155 (1994)), it is essential that such studies are complemented with measurements of PTPase activity towards cellular substrates in intact cells.

25

Phosphotyrosine recognition in signal transduction

Hormones, growth factors, cytokines, antigens, extracellular matrix components as well as molecules positioned at the cell surface induce signal transduction by binding
30 to specific cell surface structures or receptors on target cells (reviewed in Pawson, *Nature* 373: 573-580 (1995)). The resulting cellular signal is often mediated through a series of phosphorylation and dephosphorylation reactions on tyrosine residues of signaling molecules. To allow efficient and selective signaling, several recognition units for phosphotyrosine (pTyr) have developed during evolution: a) PTPases; b) Src-

homology-2 (SH2) domains; c) pTyr-binding (PTB) domains. As described above, the recognition of pTyr by PTPases leads to dephosphorylation with concomitant dissociation from the molecular target. Dephosphorylation may either lead to upregulation or downregulation of the signal. In contrast, SH2 domains and PTB domains primarily act as docking molecules with little or no catalytic activity. In other words, tyrosine phosphorylated proteins have the capacity to bind other proteins containing SH2 domains or PTB domains thereby controlling the subcellular location of signaling molecules. There appears to be a significant degree of selectivity in SH2 domain recognition of pTyr and their surroundings. Thus, SH2 domains from the Src kinase family bind the peptide pTyr-Glu-Glu-Ile in a relatively selective manner, whereas the PTPD1 seems to recognize at least five, primarily hydrophobic residues C-terminal to the pTyr (Pawson, *supra*). Certain PTPase domains, in particular the C-terminal domain of some receptor-type PTPases, seem to have little or no catalytic activity. It may be hypothesized that these domains have a function as pTyr recognition units similar to SH2 domains and PTB domains. Inhibition of signal transduction processes could, in principle, be achieved by using non-hydrolyzable pTyr-containing peptides with preferential affinity for specific PTPases, SH2 domains or PTB domains. However, due to the lack of efficient bioavailability of peptides there is a need for development of either peptidomimetics or novel small molecules with preferential binding to pTyr recognition units of specific cellular targets. Such selective compounds can either initiate, increase or decrease defined signal transduction processes.

PTPases: Inhibitors

In an early study, vanadate was found to inhibit protein-tyrosine phosphatases in mammalian cells with a concomitant increase in the level of phosphotyrosine in cellular proteins leading to transformation (Klarlund, *Cell* 41: 707-717 (1985)). Vanadium-based phosphatase inhibitors are relatively unspecific. Therefore, to assess the importance of specific structures on PTPase activity more selective inhibitors are needed. One possibility for obtaining selective PTPase inhibitors would be through design of different ancillary ligands for peroxovanadium-based compounds (Posner et al., *J. Biol. Chem.* 269: 4596-4604 (1994)). Another avenue taken by several investigators has been to incorporate nonhydrolyzable tyrosine phosphate analogs into specific peptide substrates: (1) phosphonomethyl phenylalanine (Zhang et al.,

Biochemistry 33: 2285-2290 (1994)); (2) difluorophosphono-methyl phenylalanine Burk *et al.*, *Synthesis* 11: 1019-1020 (1991)); (3) L-O-malonyltyrosine (Kole *et al.*, *Biochem. Biophys. Res. Commun.* 209: 817-822 (1995)); (4) cinnamic acid (Moran *et al.*, *J. Am. Chem. Soc.* 117: 10787-10788 (1995); Cao *et al.*, *Bioorganic Med. Chem. Lett.* 5: 2953-2958 (1995)); (5) sulfotyrosyl (Liotta *et al.*, *J. Biol. Chem.* 269: 22996-23001 (1994)). A surprising degree of selectivity is observed with simple peptide analogs containing phosphonodifluoromethyl phenylalanine as a substitute for tyrosine (Chen *et al.*, *Biochem. Biophys. Res. Commun.* 216: 976-984 (1995)). Important information has further been obtained with synthetic peptides containing sulfotyrosyl residues. A synthetic peptide corresponding to the amino acid sequence of a defined loop of the insulin receptor tyrosine kinase, Thr-Arg-Asp-Ile-Xxx-Glu-Thr-Asp-Xxx-Xxx-Arg-Lys (where Xxx denotes sulfotyrosyl), acts as a PTPase inhibitor (Liotta *et al.*, 1994, *supra*). More importantly, this peptide, when tagged with stearic acid can penetrate cells, and stimulate the action of insulin (Liotta *et al.*, 1994, *supra*).

15

PTPases: the insulin receptor signaling pathway/diabetes

Insulin is an important regulator of different metabolic processes and plays a key role in the control of blood glucose. Defects related to its synthesis or signaling lead to diabetes mellitus. Binding of insulin to its receptor causes rapid (auto)phosphorylation of several tyrosine residues in the intracellular part of the β -subunit. Three closely positioned tyrosine residues (the tyrosine-1150 domain) must all be phosphorylated to obtain full activity of the insulin receptor tyrosine kinase (IRTK) which transmits the signal further downstream by tyrosine phosphorylation of other cellular substrates, including insulin receptor substrate-1 (IRS-1) (Wilden *et al.*, *J. Biol. Chem.* 267: 16660-16668 (1992); Myers and White, *Diabetes* 42: 643-650 (1993); Lee and Pilch, *Am. J. Physiol.* 266: C319-C334 (1994); White *et al.*, *J. Biol. Chem.* 263: 2969-2980 (1988)). The structural basis for the function of the tyrosine-triplet has been provided by recent X-ray crystallographic studies of IRTK that showed tyrosine-1150 to be autoinhibitory in its unphosphorylated state (Hubbard *et al.*, *Nature* 372: 746-754 (1994)).

Several studies clearly indicate that the activity of the auto-phosphorylated IRTK can be reversed by dephosphorylation *in vitro* (reviewed in Goldstein, *Receptor* 3: 1-15 (1993); Mooney and Anderson, *J. Biol. Chem.* 264: 6850-6857 (1989)), with the tri-

35

phosphorylated tyrosine-1150 domain being the most sensitive target for protein-tyrosine phosphatases (PTPases) as compared to the di- and mono- phosphorylated forms (King *et al.*, *Biochem. J.* 275: 413-418 (1991)). It is, therefore, tempting to speculate that this tyrosine-triplet functions as a control switch of IRTK activity. Indeed, the IRTK appears to be tightly regulated by PTP-mediated dephosphorylation *in vivo* (Khan *et al.*, *J. Biol. Chem.* 264: 12931-12940 (1989); Faure *et al.*, *J. Biol. Chem.* 267: 11215-11221 (1992); Rothenberg *et al.*, *J. Biol. Chem.* 266: 8302-8311 (1991)). The intimate coupling of PTPases to the insulin signaling pathway is further evidenced by the finding that insulin differentially regulates PTPase activity in rat hepatoma cells (Meyerovitch *et al.*, *Biochemistry* 31: 10338-10344 (1992)) and in livers from alloxan diabetic rats (Boylan *et al.*, *J. Clin. Invest.* 90: 174-179 (1992)).

Relatively little is known about the identity of the PTPases involved in IRTK regulation. However, the existence of PTPases with activity towards the insulin receptor can be demonstrated as indicated above. Further, when the strong PTPase-inhibitor pervanadate is added to whole cells an almost full insulin response can be obtained in adipocytes (Fantus *et al.*, *Biochemistry* 28: 8864-8871 (1989); Eriksson *et al.*, *Diabetologia* 39: 235-242 (1995)) and skeletal muscle (Leighton *et al.*, *Biochem. J.* 276: 289-292 (1991)). In addition, recent studies show that a new class of peroxovanadium compounds act as potent hypoglycemic compounds *in vivo* (Posner *et al.*, *supra*). Two of these compounds were demonstrated to be more potent inhibitors of dephosphorylation of the insulin receptor than of the EGF-receptor.

It was recently found that the ubiquitously expressed SH2 domain containing PTPase, PTP1D (Vogel *et al.*, 1993, *supra*), associates with and dephosphorylates IRS-1, but apparently not the IR itself (Kuhné *et al.*, *J. Biol. Chem.* 268: 11479-11481 (1993); (Kuhné *et al.*, *J. Biol. Chem.* 269: 15833-15837 (1994)).

Previous studies suggest that the PTPases responsible for IRTK regulation belong to the class of membrane-associated (Faure *et al.*, *J. Biol. Chem.* 267: 11215-11221 (1992)) and glycosylated molecules (Håring *et al.*, *Biochemistry* 23: 3298-3306 (1984); Sale, *Adv. Prot. Phosphatases* 6: 159-186 (1991)). Hashimoto *et al.* have proposed that LAR might play a role in the physiological regulation of insulin receptors in intact cells (Hashimoto *et al.*, *J. Biol. Chem.* 267: 13811-13814 (1992)). Their conclusion was reached by comparing the rate of dephosphorylation/inactivation of purified IR

using recombinant PTP1B as well as the cytoplasmic domains of LAR and PTP α . Antisense inhibition was recently used to study the effect of LAR on insulin signaling in a rat hepatoma cell line (Kulas *et al.*, *J. Biol. Chem.* 270: 2435-2438 (1995)). A suppression of LAR protein levels by about 60 percent was paralleled by an
5 approximately 150 percent increase in insulin-induced auto-phosphorylation. However, only a modest 35 percent increase in IRTK activity was observed, whereas the insulin-dependent phosphatidylinositol 3-kinase (PI 3-kinase) activity was significantly increased by 350 percent. Reduced LAR levels did not alter the basal level of IRTK tyrosine phosphorylation or activity. The authors speculate that LAR
10 could specifically dephosphorylate tyrosine residues that are critical for PI 3-kinase activation either on the insulin receptor itself or on a downstream substrate.

While previous reports indicate a role of PTP α in signal transduction through src activation (Zheng *et al.*, *Nature* 359: 336-339 (1992); den Hertog *et al.*, *EMBO J.* 12:
15 3789-3798 (1993)) and interaction with GRB-2 (den Hertog *et al.*, *EMBO J.* 13: 3020-3032 (1994); Su *et al.*, *J. Biol. Chem.* 269: 18731-18734 (1994)), a recent study suggests a function for this phosphatase and its close relative PTP ϵ as negative regulators of the insulin receptor signal (Møller *et al.*, 1995 *supra*). This study also indicates that receptor-like PTPases play a significant role in regulating the IRTK,
20 whereas intracellular PTPases seem to have little, if any, activity towards the insulin receptor. While it appears that the target of the negative regulatory activity of PTPases α and ϵ is the receptor itself, the downmodulating effect of the intracellular TC-PTP seems to be due to a downstream function in the IR-activated signal. Although PTP1B and TC-PTP are closely related, PTP1B had only little influence on
25 the phosphorylation pattern of insulin-treated cells. Both PTPases have distinct structural features that determine their subcellular localization and thereby their access to defined cellular substrates (Frangione *et al.*, *Cell* 68: 545-560 (1992); Faure and Posner, *Glia* 9: 311-314 (1993)). Therefore, the lack of activity of PTP1B and TC-PTP towards the IRTK may, at least in part, be explained by the fact that they do not
30 co-localize with the activated insulin receptor. In support of this view, PTP1B and TC-PTP have been excluded as candidates for the IR-associated PTPases in hepatocytes based on subcellular localization studies (Faure *et al.*, *J. Biol. Chem.* 267: 11215-11221 (1992)).

The transmembrane PTPase CD45, which is believed to be hematopoietic cell-specific, was in a recent study found to negatively regulate the insulin receptor tyrosine kinase in the human multiple myeloma cell line U266 (Kulas *et al.*, *J. Biol. Chem.* 271: 755-760 (1996)).

5

PTPases: somatostatin

Somatostatin inhibits several biological functions including cellular proliferation (Lamberts *et al.*, *Molec. Endocrinol.* 8: 1289-1297 (1994)). While part of the
10 antiproliferative activities of somatostatin are secondary to its inhibition of hormone and growth factor secretion (e.g. growth hormone and epidermal growth factor), other antiproliferative effects of somatostatin are due to a direct effect on the target cells. As an example, somatostatin analogs inhibit the growth of pancreatic cancer presumably via stimulation of a single PTPase, or a subset of PTPases, rather than a general
15 activation of PTPase levels in the cells (Liebow *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2003-2007 (1989); Colas *et al.*, *Eur. J. Biochem.* 207: 1017-1024 (1992)). In a recent study it was found that somatostatin stimulation of somatostatin receptors SSTR1, but not SSTR2, stably expressed in CHO-K1 cells can stimulate PTPase activity and that this stimulation is pertussis toxin-sensitive. Whether the inhibitory effect of
20 somatostatin on hormone and growth factor secretion is caused by a similar stimulation of PTPase activity in hormone producing cells remains to be determined.

25 PTPases: the immune system/autoimmunity

Several studies suggest that the receptor-type PTPase CD45 plays a critical role not only for initiation of T cell activation, but also for maintaining the T cell receptor-mediated signaling cascade. These studies are reviewed in: Weiss A., *Ann. Rev.*
30 *Genet.* 25: 487-510 (1991); Chan *et al.*, *Annu. Rev. Immunol.* 12: 555-592 (1994); Trowbridge and Thomas, *Annu. Rev. Immunol.* 12: 85-116 (1994).

The exact function of CD45 in lymphocyte activation is currently under intense investigation in many laboratories. Several studies suggest that the PTPase activity of
35 CD45 plays a role in the activation of Lck, a lymphocyte-specific member of the Src

family protein-tyrosine kinase (Mustelin *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 6302-6306 (1989); Ostergaard *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 8959-8963 (1989)). These authors hypothesized that the phosphatase activity of CD45 activates Lck by dephosphorylation of a C-terminal tyrosine residue, which may, in turn, be related to T-cell activation. In a recent study it was found that recombinant p56^{lck} specifically associates with recombinant CD45 cytoplasmic domain protein, but not to the cytoplasmic domain of the related PTP α (Ng *et al.*, *J. Biol. Chem.* 271: 1295-1300 (1996)). The p56^{lck}-CD45 interaction seems to be mediated via a nonconventional SH2 domain interaction not requiring phosphotyrosine. In immature B cells, another member of the Src family protein-tyrosine kinases, Fyn, seems to be a selective substrate for CD45 compared to Lck and Syk (Katagiri *et al.*, *J. Biol. Chem.* 270: 27987-27990 (1995)).

HePTP, a hematopoietic cell specific PTPase, is induced after activation of resting T cells and may play a role in late T cell activation or as a negative regulator of T cell responses (Zanke *et al.*, *Eur. J. Immunol.* 22: 235-239 (1992)). Likewise, the hematopoietic cell specific PTP1C seems to act as a negative regulator and play an essential role in immune cell development. In accordance with the above-mentioned important function of CD45, HePTP and PTP1C, selective PTPase inhibitors may be attractive drug candidates both as immunosuppressors and as immunostimulants. One recent study illustrates the potential of PTPase inhibitors as immunomodulators by demonstrating the capacity of the vanadium-based PTPase inhibitor, BMLOV, to induce apparent B cell selective apoptosis compared to T cells (Schieven *et al.*, *J. Biol. Chem.* 270: 20824-20831 (1995)).

25

PTPases: cell-cell interactions/cancer

Focal adhesion plaques, an *in vitro* phenomenon in which specific contact points are formed when fibroblasts grow on appropriate substrates, seem to mimic, at least in part, cells and their natural surroundings. Several focal adhesion proteins are phosphorylated on tyrosine residues when fibroblasts adhere to and spread on extracellular matrix (Gumbiner, *Neuron* 11, 551-564 (1993)). However, aberrant tyrosine phosphorylation of these proteins can lead to cellular transformation. The intimate association between PTPases and focal adhesions is supported by the finding of several intracellular PTPases with ezrin-like N-terminal domains, e.g.

35

PTPMEG1 (Gu *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 5867-5871 (1991)), PTPH1 (Yang and Tonks, *Proc. Natl. Acad. Sci. USA* 88: 5949-5953 (1991)) and PTPD1 (Møller *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 7477-7481 (1994)). The ezrin-like domain show similarity to several proteins that are believed to act as links between the cell membrane and the cytoskeleton. PTPD1 was found to be phosphorylated by and associated with c-src *in vitro* and is hypothesized to be involved in the regulation of phosphorylation of focal adhesions (Møller *et al.*, *supra*).

PTPases may oppose the action of tyrosine kinases, including those responsible for phosphorylation of focal adhesion proteins, and may therefore function as natural inhibitors of transformation. TC-PTP, and especially the truncated form of this enzyme (Cool *et al.*, *Proc. Natl. Acad. Sci. USA* 87: 7280-7284 (1990)), can inhibit the transforming activity of v-erb and v-fms (Lammers *et al.*, *J. Biol. Chem.* 268: 22456-22462 (1993); Zander *et al.*, *Oncogene* 8: 1175-1182 (1993)). Moreover, it was found that transformation by the oncogenic form of the *HER2/neu* gene was suppressed in NIH 3T3 fibroblasts overexpressing PTP1B (Brown-Shimer *et al.*, *Cancer Res.* 52: 478-482 (1992)).

The expression level of PTP1B was found to be increased in a mammary cell line transformed with *neu* (Zhay *et al.*, *Cancer Res.* 53: 2272-2278 (1993)). The intimate relationship between tyrosine kinases and PTPases in the development of cancer is further evidenced by the recent finding that PTP ϵ is highly expressed in murine mammary tumors in transgenic mice over-expressing c-*neu* and v-Ha-*ras*, but not c-*myc* or *int-2* (Elson and Leder, *J. Biol. Chem.* 270: 26116-26122 (1995)). Further, the human gene encoding PTP γ was mapped to 3p21, a chromosomal region which is frequently deleted in renal and lung carcinomas (LaForgia *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 5036-5040 (1991)).

In this context, it seems significant that PTPases appear to be involved in controlling the growth of fibroblasts. In a recent study it was found that Swiss 3T3 cells harvested at high density contain a membrane-associated PTPase whose activity on an average is 8-fold higher than that of cells harvested at low or medium density (Pallen and Tong, *Proc. Natl. Acad. Sci. USA* 88: 6996-7000 (1991)). It was hypothesized by the authors that density-dependent inhibition of cell growth involves the regulated elevation of the activity of the PTPase(s) in question. In accordance with this view, a novel membrane-

bound, receptor-type PTPase, DEP-1, showed enhanced (≥ 10 -fold) expression levels with increasing cell density of WI-38 human embryonic lung fibroblasts and in the AG1518 fibroblast cell line (Östman *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 9680-9684 (1994)).

5

Two closely related receptor-type PTPases, PTP κ and PTP μ , can mediate homophilic cell-cell interaction when expressed in non-adherent insect cells, suggesting that these PTPases might have a normal physiological function in cell-to-cell signaling (Gebbink *et al.*, *J. Biol. Chem.* 268: 16101-16104 (1993); Brady-Kalnay *et al.*, *J. Cell Biol.* 122: 961-972 (1993); Sap *et al.*, *Mol. Cell. Biol.* 14: 1-9 (1994)). Interestingly, PTP κ and PTP μ do not interact with each other, despite their structural similarity (Zondag *et al.*, *J. Biol. Chem.* 270: 14247-14250 (1995)). From the studies described above it is apparent that PTPases may play an important role in regulating normal cell growth. However, as pointed out above, recent studies indicate that PTPases may also function as positive mediators of intracellular signaling and thereby induce or enhance mitogenic responses. Increased activity of certain PTPases might therefore result in cellular transformation and tumor formation. Indeed, in one study over-expression of PTP α was found to lead to transformation of rat embryo fibroblasts (Zheng, *supra*). In addition, a novel PTP, SAP-1, was found to be highly expressed in pancreatic and colorectal cancer cells. SAP-1 is mapped to chromosome 19 region q13.4 and might be related to carcinoembryonic antigen mapped to 19q13.2 (Uchida *et al.*, *J. Biol. Chem.* 269: 12220-12228 (1994)). Further, the dsPTPase, cdc25, dephosphorylates cdc2 at Thr14/Tyr-15 and thereby functions as positive regulator of mitosis (reviewed by Hunter, *Cell* 80: 225-236 (1995)). Inhibitors of specific PTPases are therefore likely to be of significant therapeutic value in the treatment of certain forms of cancer.

PTPases: platelet aggregation

Recent studies indicate that PTPases are centrally involved in platelet aggregation. Agonist-induced platelet activation results in calpain-catalyzed cleavage of PTP1B with a concomitant 2-fold stimulation of PTPase activity (Frangioni *et al.*, *EMBO J.* 12: 4843-4856 (1993)). The cleavage of PTP1B leads to subcellular relocation of the enzyme and correlates with the transition from reversible to irreversible platelet

aggregation in platelet-rich plasma. In addition, the SH2 domain containing PTPase, PTP1C/SH-PTP1, was found to translocate to the cytoskeleton in platelets after thrombin stimulation in an aggregation-dependent manner (Li *et al.*, *FEBS Lett.* 343: 89-93 (1994)).

5

Although some details in the above two studies were recently questioned there is over-all agreement that PTP1B and PTP1C play significant functional roles in platelet aggregation (Ezumi *et al.*, *J. Biol. Chem.* 270: 11927-11934 (1995)). In accordance with these observations, treatment of platelets with the PTPase inhibitor pervanadate
10 leads to significant increase in tyrosine phosphorylation, secretion and aggregation (Pumiglia *et al.*, *Biochem. J.* 286: 441-449 (1992)).

PTPases: osteoporosis

15

The rate of bone formation is determined by the number and the activity of osteoblasts, which in turn are determined by the rate of proliferation and differentiation of osteoblast progenitor cells, respectively. Histomorphometric studies indicate that the osteoblast number is the primary determinant of the rate of bone
20 formation in humans (Gruber *et al.*, *Mineral Electrolyte Metab.* 12: 246-254 (1987); reviewed in Lau *et al.*, *Biochem. J.* 257: 23-36 (1989)). Acid phosphatases/PTPases may be involved in negative regulation of osteoblast proliferation. Thus, fluoride, which has phosphatase inhibitory activity, has been found to increase spinal bone density in osteoporotics by increasing osteoblast proliferation (Lau *et al.*, *supra*). Consistent with
25 this observation, an osteoblastic acid phosphatase with PTPase activity was found to be highly sensitive to mitogenic concentrations of fluoride (Lau *et al.*, *J. Biol. Chem.* 260: 4653-4660 (1985); Lau *et al.*, *J. Biol. Chem.* 262: 1389-1397 (1987); Lau *et al.*, *Adv. Protein Phosphatases* 4: 165-198 (1987)). Interestingly, it was recently found that the level of membrane-bound PTPase activity was increased dramatically when the
30 osteoblast-like cell line UMR 106.06 was grown on collagen type-I matrix compared to uncoated tissue culture plates. Since a significant increase in PTPase activity was observed in density-dependent growth arrested fibroblasts (Pallen and Tong, *Proc. Natl. Acad. Sci.* 88: 6996-7000 (1991)), it might be speculated that the increased PTPase activity directly inhibits cell growth. The mitogenic action of fluoride and other
35 phosphatase inhibitors (molybdate and vanadate) may thus be explained by their

inhibition of acid phosphatases/PTPases that negatively regulate the cell proliferation of osteoblasts. The complex nature of the involvement of PTPases in bone formation is further suggested by the recent identification of a novel parathyroid regulated, receptor-like PTPase, OST-PTP, expressed in bone and testis (Mauro *et al.*, *J. Biol. Chem.* 269: 30659-30667 (1994)). OST-PTP is up-regulated following differentiation and matrix formation of primary osteoblasts and subsequently down-regulated in the osteoblasts which are actively mineralizing bone in culture. It may be hypothesized that PTPase inhibitors may prevent differentiation via inhibition of OST-PTP or other PTPases thereby leading to continued proliferation. This would be in agreement with the above-mentioned effects of fluoride and the observation that the tyrosine phosphatase inhibitor orthovanadate appears to enhance osteoblast proliferation and matrix formation (Lau *et al.*, *Endocrinology* 116: 2463-2468 (1988)). In addition, it was recently observed that vanadate, vanadyl and pervanadate all increased the growth of the osteoblast-like cell line UMR106. Vanadyl and pervanadate were stronger stimulators of cell growth than vanadate. Only vanadate was able to regulate the cell differentiation as measured by cell alkaline phosphatase activity (Cortizo *et al.*, *Mol. Cell. Biochem.* 145: 97-102 (1995)).


PTPases: microorganisms

Dixon and coworkers have called attention to the fact that PTPases may be a key element in the pathogenic properties of *Yersinia* (reviewed in Clemens *et al.* *Molecular Microbiology* 5: 2617-2620 (1991)). This finding was rather surprising since tyrosine phosphate is thought to be absent in bacteria. The genus *Yersinia* comprises 3 species: *Y. pestis* (responsible for the bubonic plague), *Y. pseudotuberculosis* and *Y. enterocolitica* (causing enteritis and mesenteric lymphadenitis). Interestingly, a dual-specificity phosphatase, VH1, has been identified in Vaccinia virus (Guan *et al.*, *Nature* 350: 359-263 (1991)). These observations indicate that PTPases may play critical roles in microbial and parasitic infections, and they further point to PTPase inhibitors as a novel, putative treatment principle of infectious diseases.

SUMMARY OF THE INVENTION

The inventors have identified a novel class of compounds that has the capacity to modulate the activity of molecules with tyrosine recognition units, including PTPases,

preferably a selective modulation. In one aspect, the present invention relates to novel acrylic acids of general formula (I)



5 (I)


wherein

(L)_n, n, Ar₁, and R₁ are defined as below.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel acrylic acids of formula (I)



(I)

wherein

20 n is 1, 2, 3, 4, or 5 and (L)_n represents up to five (5) substituents which independently of each other are hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, hydroxy, halogen, trihalogenomethyl, hydroxy-C₁₋₆-alkyl, amino-C₁₋₆-alkyl, COR₂, NO₂, CN, CHO, C₁₋₆-alkanoyloxy, carbamoyl, NR₅R₆, aryloxy optionally substituted; R₂ is C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted, OH, NR₃R₄ wherein R₃ and R₄ independently of each other are hydrogen, C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted;

25

R₅ and R₆ are independently of each other hydrogen, C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted or COZ, wherein Z, is C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted;

30

L is A-Y₁-(W₁)-X-(W₂)-Y₂ wherein X is a chemical bond, CO, CONR₇, NR₇CO, NR₇, O, S, SO, or SO₂;

Y₁ and Y₂ are independently a chemical bond, O, S, or NR₇;

R₇ is hydrogen, C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted,

heteroaryl optionally substituted, COZ₂ wherein Z₂ is C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted;

W₁ and W₂ are independently a chemical bond or saturated or unsaturated C₁₋₆-alkylene;

A is aryl optionally substituted, heteroaryl optionally substituted, biaryl optionally substituted, arylheteroaryl optionally substituted, NR₈R₉ wherein R₈ and R₉ independently are hydrogen, C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted, COZ₃ wherein Z₃ is C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted or when R₈ and R₉ together with the nitrogen atom forms a ring system A is a saturated or partially saturated heterocyclic ring system optionally substituted with C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted, OH, C₁₋₆-alkoxy, hydroxy-C₁₋₆-alkyl, amino-C₁₋₆-alkyl, COZ₄ wherein Z₄ is OH, C₁₋₆-alkyl, NR₁₀R₁₁ wherein R₁₀ and R₁₁ independently are hydrogen, C₁₋₆-alkyl, R₁ is hydrogen, C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted;

and Ar₁ is aryl or heteroaryl;

or a pharmaceutically acceptable salt thereof.

In the above-mentioned formula (I) aryl, heteroaryl, Ar₁ and A are exemplified by the following examples. Specific examples of the aryl and biaryl residues include phenyl, biphenyl, indene, fluorene, naphthyl (1-naphthyl, 2-naphthyl), anthracene (1-anthracenyl, 2-anthracenyl, 3-anthracenyl). Specific examples of the heteroaryl include pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl, 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl),

benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl, (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro-benzo[b]thiophenyl, (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,f]azepine (5H-dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H-dibenz[b,f]azepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11-dihydro-5H-dibenz[b,f]azepine (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-2-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-5-yl), 5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-1-yl, 5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-yl, 5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-3-yl, 5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-4-yl, piperidinyl (2-piperidinyl, 3-piperidinyl, 4-piperidinyl), pyrrolidinyl (1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl), morpholinyl (1-morpholinyl, 2-morpholinyl), piperazinyl (1-piperazinyl).

Specific examples of the arylheteroaryl residue include phenylpyridyl (2-phenylpyridyl, 3-phenylpyridyl, 4-phenylpyridyl), phenylpyrimidinyl (2-phenylpyrimidinyl, 4-phenylpyrimidinyl, 5-phenylpyrimidinyl, 6-phenylpyrimidinyl), phenylpyrazinyl, phenylpyridazinyl (3-phenylpyridazinyl, 4-phenylpyridazinyl, 5-phenylpyridazinyl).

In the above mentioned compound of formula (I) examples of L is quinolinyl-piperazineylethyl such as 2-(4-quinolin-2-yl-piperazin-1-yl)ethyl, biphenyloxymethyl such as biphenyl-4-yloxymethyl, phenyl-piperazinylmethyl such as 4-phenylpiperazin-

1-ylmethyl, biphenylmethyl such as 1-biphenyl-4-ylmethyl.

The C₁₋₆-alkyl residues include aliphatic hydrocarbon residues, unsaturated aliphatic hydrocarbon residues, alicyclic hydrocarbon residues. Examples of the aliphatic hydrocarbon residues include saturated aliphatic hydrocarbon residues having 1 to 6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.butyl, tert.butyl, n-pentyl, isopentyl, neopentyl, tert.pentyl, n-hexyl, isohexyl. Example of the unsaturated aliphatic hydrocarbon residues include those having 2 to 6 carbon atoms such as ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, ethynyl, 1-propionyl, 2-propionyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 3-hexynyl, 2,4-hexadiynyl, 5-hexynyl. Examples of the alicyclic hydrocarbon residue include saturated alicyclic hydrocarbon residues having 3 to 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; and C₅₋₆ unsaturated alicyclic hydrocarbon residues having 5 to 6 carbon atoms such as 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl.

The C₁₋₆-alkoxy residues include aliphatic hydrocarbon residues connected to an oxygen atom. Examples of the aliphatic hydrocarbon residues include saturated aliphatic hydrocarbon residues having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, iso-propoxy, butoxy, isobutoxy, sec.butoxy, tert.butoxy, pentoxy, isopentoxy, neopentoxy, tert.pentoxy, hexyloxy, isohexyloxy.

The C₁₋₆-alkoxycarbonyl residues include a C₁₋₆-alkoxy residue connected to a carbonyl residue such as methoxycarbonyl, ethoxy-carbonyl, propoxycarbonyl, and tert-butoxycarbonyl.

The C₁₋₆-alkanoyloxy residues include an acyl residue connected to an oxygen atom wherein the acyl residue is an aliphatic hydrocarbon residues connected to a carbonyl residue such as acetyloxy, propionyloxy, isopropionyloxy.

The aralkyl residue include an aryl residue connected to an C₁₋₆-alkyl residue e.g. phenyl alkyls having 7 to 9 carbon atoms such as benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-phenylpropyl and 1-phenylpropyl; and naphthyl alkyl having 11 to 13

carbon atoms such as 1-naphthylmethyl, 1-naphthylethyl, 2-naphthylmethyl, and 2-naphthylethyl.

Aryloxy include an aryl connected to an oxygen atom such as phenyloxy, naphthyloxy.

5

Aralkyloxy include an aralkyl connected to an oxygen atom such as benzyloxy, phenethyloxy, naphthylmethyloxy.

Biaryl include an aryl connected to an aryl residue such as biphenyl, 1-

10 phenylnaphthyl, 2-phenylnaphthyl .

Biaryloxy include an biaryl connected to an oxygen atom such as biphenyl ether, 1-naphthylphenyl ether, 2-naphthylphenyl ether.

15 The heteroaryl residue is a 5- or 6-membered aromatic ring, which can be fused to one or more phenyl rings and contains, besides carbon atoms, 1 to 4 atoms selected from N, O, and S as atoms constituting the ring, which is bonded through carbon atoms such as defined above.

20 The halogen residue include fluorine, chlorine, bromine, and iodine.

The term "optionally substituted" means an aryl residue, a heteroaryl residue, or a C₁₋₆-alkyl residue that may be unsubstituted or may have 1 or more preferably 1 to 5 substituents, which are the same as or different from one another. Examples of these
 25 substituents include, halogen (fluorine, chlorine, bromine, iodine), hydroxyl, cyano, nitro, trifluoromethyl, carbamoyl, C₁₋₄-acyl (e.g. acetyl, propionyl, isopropionyl), C₁₋₆-alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, and tert.butoxy), C₁₋₆-alkyl (e.g. methyl, ethyl, propyl, cyclopropyl, isopropyl, butyl, and tert.butyl), C₁₋₆-alkoxycarbonyl (e.g. ones having 2 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, and propoxycarbonyl), C₁₋₆-alkanoyloxy (e.g. ones having 2 to 6
 30 carbon atoms such as acetyloxy, propionyloxy, isopropionyloxy), C₁₋₄-alkylthio (e.g. ones having 1 to 4 carbon atoms such as methylthio, ethylthio, propylthio, and isopropylthio), C₁₋₄-alkylamino (e.g. one having 1 to 4 carbon atoms such as methylamino, ethylamino, dimethylamino, and 1-pyrrolidinyl), heteroaryl (as
 35 exemplified above), aryloxy (e.g. phenyloxy), and a aralkyloxy (e.g. benzyloxy).

The compounds of formula (I) may exist as geometric and optical isomers and all isomers and mixtures thereof are included herein. Isomers may be separated by means of standard methods such as chromatographic techniques or fractionated
 5 crystallisation of e.g. suitable salts.

The compounds according to the invention may optionally exist as pharmaceutically acceptable salts comprising acid addition salts or metal salts or - optionally alkylated - ammonium salts.


10

Examples of such salts include the alkali metal or amine salts of 1H- or 2H-tetrazoles of this invention, such as the sodium, potassium, C₁₋₆-alkylamine, di (C₁₋₆-alkyl) amine, tri (C₁₋₆-alkyl) amine and the four (4) corresponding omega-hydroxy analogues (e.g. methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine,
 15 trimethylamine, triethylamine, tripropylamine, di(hydroxyethyl)amine, and the like;

inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate or similar pharmaceutically acceptable inorganic or organic acid addition salts, and
 20 include the pharmaceutically acceptable salts listed in *Journal of Pharmaceutical Science* 66: 2 (1977) which are hereby incorporated by reference.

The compounds of formula (I) may be prepared by art-recognised procedures from known compounds or readily preparable intermediates. An exemplary general
 25 procedure is as follows:


Method A:



30 By allowing a compound of formula (II), wherein (L)_n, n, and Ar₁ are as defined above and X₁ is a suitable leaving group such as bromo, iodo or triflate to react with a compound of formula (III) wherein R₁ is defined as above.

These reactions may be carried out in a solvent such as triethylamine (TEA), methanol, ethanol or dimethylsulfoxide (DMSO) in the presence of a palladium catalyst, e.g. (Pd/C, Pd/Al₂O₃, Pd/BaSO₄, Pd/SiO₂ or Pd(OAc)₂) and a triaryl-phosphine catalyst as e.g. (triphenyl-phosphine or tri-*o*-tolyl-phosphine) at temperatures ranging
 5 from 50 °C to 150 °C for 1 to 60 hours.

Method B:



10 By allowing a compound of formula (IV), wherein (L)_n, n, and Ar₁ are as defined above to react with a compound of formula (V) wherein R₁ is as defined above and L_w is trimethylsilyl (a Peterson reaction), triphenylphosphonium (a Wittig reaction), diethyl phosphate (a modified Wittig reaction) or carbonyloxyC₁₋₆-alkyl (e.g. COOEt or COOMe);

15

These reactions may be carried out in a solvent such as methanol, ethanol, tetrahydrofuran (THF), toluene, N,N-dimethylformamide (DMF) or dimethylsulfoxide (DMSO) in the presence of a base such as triethylamine, pyridine, piperidine, sodium hydride, sodium methoxide, sodium ethoxide, sodium hydroxide, potassium tert-
 20 butoxide, lithium diisopropylamide at temperatures ranging from -50°C to 150°C for 1 to 60 hours.

Compounds of formula (II), (III) (IV) or (V) may be prepared by methods familiar to those skilled in the art or may be commercially available.

25

Under certain circumstances it may be necessary to protect the intermediates used in the above methods. Introduction and removal of such groups is e.g. described in "Protective Groups in Organic Synthesis" T.W. Greene and P.G.M. Wuts, ed. Second edition (1991).

30

In preferred embodiments, the compounds of the invention modulate the activity of protein tyrosine phosphatases or other molecules with phosphotyrosine recognition unit(s).

In one preferred embodiment the compounds of the invention act as inhibitors of PTPases, e.g. protein tyrosine phosphatases involved in regulation of tyrosine kinase signaling pathways. Preferred embodiments include modulation of receptor-tyrosine kinase signaling pathways via interaction with regulatory PTPases, e.g. the signaling pathways of the insulin receptor, the IGF-I receptor and other members of the insulin receptor family, the EGF-receptor family, the platelet-derived growth factor receptor family, the nerve growth factor receptor family, the hepatocyte growth factor receptor family, the growth hormone receptor family and members of other receptor-type tyrosine kinase families. Further preferred embodiments of the inventions is modulation of non-receptor tyrosine kinase signaling through modulation of regulatory PTPases, e.g. modulation of members of the Src kinase family. One type of preferred embodiments of the inventions relate to modulation of the activity of PTPases that negatively regulate signal transduction pathways. Another type of preferred embodiments of the inventions relate to modulation of the activity of PTPases that positively regulate signal transduction pathways.

In a preferred embodiment the compounds of the invention act as modulators of the active site of PTPases. In another preferred embodiment the compounds of the invention modulate the activity of PTPases via interaction with structures positioned outside of the active sites of the enzymes, preferably SH2 domains. Further preferred embodiments include modulation of signal transduction pathways via binding of the compounds of the invention to SH2 domains or PTB domains of non-PTPase signaling molecules.

25

Other preferred embodiments include use of the compounds of the invention for modulation of cell-cell interactions as well as cell-matrix interactions.

As a preferred embodiment, the present invention include within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of formula (I) in association with a pharmaceutical carrier or diluent. Optionally, the pharmaceutical composition can comprise at least one of the compounds of formula (I) combined with compounds exhibiting a different activity, e.g. an antibiotic or other pharmacologically active material.

As a preferred embodiment, the compounds of the invention may be used as therapeutics to inhibit of PTPases involved in regulation of the insulin receptor tyrosine kinase signaling pathway in patients with type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, and obesity. Further preferred
5 embodiments include use of the compounds of the invention for treatment of disorders with general or specific dysfunctions of PTPase activity, e.g. proliferative disorders such as psoriasis and neoplastic diseases. As another embodiment, the compounds of the invention may be used in pharmaceutical preparations for treatment of
10 osteoporosis.

Preferred embodiments of the invention further include use of compound of formula (I) in pharmaceutical preparations to increase the secretion or action of growth hormone and its analogs or somatomedins including IGF-1 and IGF-2 by modulating the activity
15 of PTPases or other signal transduction molecules with affinity for phosphotyrosine involved controlling or inducing the action of these hormones or any regulating molecule.

To those skilled in the art, it is well known that the current and potential uses of growth
20 hormone in humans are varied and multi-tudinous. Thus, compounds of the invention can be administered for purposes of stimulating the release of growth hormone from the pituitary or increase its action on target tissues thereby leading to similar effects or uses as growth hormone itself. The uses of growth hormone may be summarized as follows: stimulation of growth hormone release in the elderly; prevention of catabolic
25 side effects of glucocorticoids; treatment of osteoporosis, stimulation of the immune system; treatment of retardation, acceleration of wound healing; accelerating bone fracture repair; treatment of growth retardation; treating renal failure or insufficiency resulting in growth retardation; treatment of physiological short stature including growth hormone deficient children and short stature associated with chronic illness;
30 treatment of obesity and growth retardation associated with obesity; treating growth retardation associated with the Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients; treatment of intrauterine growth retardation, skeletal dysplasia, hypercortisolism and Cushing's syndrome; induction of pulsatile growth hormone release; replacement of growth
35 hormone in stressed patients; treatment of osteochondro-dysplasias, Noonans

syndrome, schizophrenia, depressions, Alzheimer's disease, delayed wound healing and psychosocial deprivation; treatment of pulmonary dysfunction and ventilator dependency; attenuation of protein catabolic responses after major surgery; reducing cachexia and protein loss due to chronic illness such as cancer or AIDS; treatment of

5 hyperinsulinemia including nesidio-blastosis; Adjuvant treatment for ovulation induction; stimulation of thymic development and prevention the age-related decline of thymic function; treatment of immunosuppressed patients; improvement in muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis, renal hemeostasis in the frail elderly; stimulation of osteoblasts, bone remodelling and

10 cartilage growth; stimulation of the immune system in companion animals and treatment of disorder of aging in companion animals; growth promotant in livestock and stimulation of wool growth in sheep.

The compounds of the invention may be used in pharmaceutical preparations for

15 treatment of various disorders of the immune system, either as a stimulant or suppressor of normal or perturbed immune functions, including autoimmune reactions. Further embodiments of the invention include use of the compounds of the invention for treatment of allergic reactions, e.g. asthma, dermal reactions, conjunctivitis.

20 In another embodiment compounds of the invention may be used in pharmaceutical preparations for prevention or induction of platelet aggregation.

In yet another embodiment, compounds of the invention may be used in pharmaceutical preparations for treatment of infectious disorders. In particular, the

25 compounds of the invention may be used for treatment of infectious disorders caused by *Yersinia* and other bacteria as well as disorders caused by viruses or other micro-organisms.

Compounds of the invention may additionally be used for treatment or prevention of

30 diseases in animals, including commercially important animals.

Also included in the present invention is a process for isolation of PTPases via affinity purification procedures based on the use of immobilized compounds of the invention using procedures well-known to those skilled in the art.

The invention is further directed to a method for detecting the presence of PTPases in cell or in a subject comprising:

- (a) contacting said cell or an extract thereof with labeled compounds of the invention.
- (b) detecting the binding of the compounds of the invention or measuring the quantity bound, thereby detecting the presence or measuring the quantity of certain PTPases.

- 10 The invention further relates to analysis and identification of the specific functions of certain PTPases by modulating their activity by using compounds of the invention in cellular assay systems or in whole animals.

DEFINITIONS

- 15 Signal transduction is a collective term used to define all cellular processes that follow the activation of a given cell or tissue. Examples of signal transduction, which are not intended to be in any way limiting to the scope of the invention claimed, are cellular events that are induced by polypeptide hormones and growth factors (e.g. insulin, insulin-like growth factors I and II, growth hormone, epidermal growth factor, platelet-derived growth factor), cytokines (e.g. inter-leukins), extracellular matrix components, and cell-cell interactions.

- 25 Phosphotyrosine recognition units/tyrosine phosphate recognition units/pTyr recognition units are defined as areas or domains of proteins or glycoproteins that have affinity for molecules containing phosphorylated tyrosine residues (pTyr). Examples of pTyr recognition units, which are not intended to be in any way limiting to the scope of the invention claimed, are: PTPases, SH2 domains and PTB domains.

- 30 PTPases are defined as enzymes with the capacity to dephosphorylate pTyr-containing proteins or glycoproteins. Examples of PTPases, which are not intended to be in any way limiting to the scope of the invention claimed, are: 'classical' PTPases (intracellular PTPases (e.g. PTP1B, TC-PTP, PTP1C, PTP1D, PTPD1, PTPD2) and receptor-type PTPases (e.g. PTP α , PTP ϵ , PTP β , PTP γ , CD45, PTP κ , PTP μ), dual specificity phosphatases (VH1, VHR, cdc25), LMW-PTPases or acid phosphatases.
- 35

Modulation of cellular processes is defined as the capacity of compounds of the invention to 1) either increase or decrease ongoing, normal or abnormal, signal transduction, 2) initiate normal signal transduction, and 3) initiate abnormal signal transduction.

Modulation of pTyr-mediated signal transduction/modulation of the activity of molecules with pTyr recognition units is defined as the capacity of compounds of the invention to 1) increase or decrease the activity of proteins or glycoproteins with pTyr recognition units (e.g. PTPases, SH2 domains or PTB domains) or to 2) decrease or increase the association of a pTyr-containing molecule with a protein or glyco-protein with pTyr recognition units either via a direct action on the pTyr recognition site or via an indirect mechanism. Examples of modulation of pTyr-mediated signal transduction/modulation of the activity of molecules with pTyr recognition units, which are not intended to be in any way limiting to the scope of the invention claimed, are: a) inhibition of PTPase activity leading to either increased or decreased signal transduction of ongoing cellular processes; b) inhibition of PTPase activity leading to initiation of normal or abnormal cellular activity; c) stimulation of PTPase activity leading to either increased or decreased signal transduction of ongoing cellular processes; d) stimulation of PTPase activity leading to initiation of normal or abnormal cellular activity; e) inhibition of binding of SH2 domains or PTB domains to proteins or glycoproteins with pTyr leading to increase or decrease of ongoing cellular processes; f) inhibition of binding of SH2 domains or PTB domains to proteins or glycoproteins with pTyr leading to initiation of normal or abnormal cellular activity.

25

A subject is defined as any mammalian species, including humans.

Pharmacological Methods

For the above indications the dosage will vary depending on the compound of formula (I) employed, on the mode of administration and on the therapy desired. However, in general, satisfactory results are obtained with a dosage of from about 0.5 mg to about 1000 mg, preferably from about 1 mg to about 500 mg of compounds of formula (I), conveniently given from 1 to 5 times daily, optionally in sustained release form.

Usually, dosage forms suitable for oral administration comprise from about 0.5 mg to

about 1000 mg, preferably from about 1 mg to about 500 mg of the compounds of formula (I) admixed with a pharmaceutical carrier or diluent.

- The compounds of formula (I) may be administered in a pharmaceutically acceptable
5 acid addition salt form or where possible as a metal or a C₁₋₆-alkylammonium salt.
Such salt forms exhibit approximately the same order of activity as the free acid forms.

- This invention also relates to pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and, usually, such
10 compositions also contain a pharmaceutical carrier or diluent. The compositions containing the compounds of this invention may be prepared by conventional techniques and appear in conventional forms, for example capsules, tablets, solutions or suspensions.

- 15 The pharmaceutical carrier employed may be a conventional solid or liquid carrier. Examples of solid carriers are lactose, terra alba, sucrose, talc, gelatine, agar, pectin, acacia, magnesium stearate and stearic acid. Examples of liquid carriers are syrup, peanut oil, olive oil and water.
- 20 Similarly, the carrier or diluent may include any time delay material known to the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

- If a solid carrier for oral administration is used, the preparation can be tableted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a
25 troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

- 30 Generally, the compounds of this invention are dispensed in unit dosage form comprising 10-200 mg of active ingredient in or together with a pharmaceutically acceptable carrier per unit dosage.

- The dosage of the compounds according to this invention is 1-500 mg/day, e.g. about
35 100 mg per dose, when administered to patients, e.g. humans, as a drug.

A typical tablet which may be prepared by conventional tableting techniques contains

Core:

5	Active compound (as free compound or salt thereof)	100 mg
	Colloidal silicon dioxide (Areosil®)	1.5 mg
	Cellulose, microcryst. (Avicel®)	70 mg
	Modified cellulose gum (Ac-Di-Sol®)	7.5 mg
10	Magnesium stearate	

Coating:

	HPMC	approx.	9 mg
	*Mywacett® 9-40 T	approx.	0.9 mg

15

*Acylated monoglyceride used as plasticiser for film coating.

The route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g.

20 rectal, transdermal, subcutaneous, intranasal, intramuscular, topical, intravenous, intraurethral, ophthalmic solution or an ointment, the oral route being preferred.

Additionally the compounds of formula I may be useful *in vitro* and/or *in vivo* diagnostic tools.

25

EXAMPLES

The process for preparing compounds of formula (I) and preparations containing them is further illustrated in the following examples, which, however, are not to be construed

30 as limiting.

Hereinafter, TLC is thin layer chromatography, CDCl₃ is deuterio chloroform and DMSO-d₆ is hexadeuterio dimethylsulfoxide. The structures of the compounds are confirmed by either elemental analysis or NMR, where peaks assigned to

35 characteristic protons in the title compounds are presented where appropriate. ¹H

NMR shifts (δ_H) are given in parts per million (ppm) downfield from tetramethylsilane as internal reference standard. M.p. is melting point and is given in °C and is not corrected. Column chromatography was carried out using the technique described by W.C. Still *et al.*, *J. Org. Chem.* 43: 2923 (1978) on Merck silica gel 60 (Art. 9385).


- 5 HPLC analyses were performed using 5 μ m C18 4 x 250 mm column eluted with various mixtures of water and acetonitrile, flow = 1 ml/min, as described in the experimental section.

Compounds used as starting materials are either known compounds or compounds which can readily be prepared by methods known per se.

10

EXAMPLE 1

3-(3-(Biphenyl-4-yloxy)methyl)phenyl)acrylic acid



15

To a solution of 4-phenylphenol (6.13 g, 36 mmol) in dry N,N-dimethyl-formamide (100 ml) kept under an atmosphere of nitrogen, sodium hydride (1.73 g, 43.2 mmol, 60 % dispersion in mineral oil) was added in portions and the reaction mixture was stirred until gas evolution ceased. 3-Bromobenzyl bromide (10.0 g, 39.61 mmol) was added

20 in portions and the reaction mixture was stirred at room temperature for 18 h. To the reaction mixture water (50 ml) was added. The precipitate was filtered off and washed with water (3 x 100 ml), 96 % ethanol (2 x 30 ml), diethyl ether (2 x 80 ml), and dried in vacuo at 50 °C for 18 h affording 11.64 g (95 %) of 4-(3-bromo-benzyloxy)biphenyl as a solid.

25

A mixture of the above biphenyl (5.0 g, 14.74 mmol), tert-butyl acrylate (2.98 ml, 19.16 mmol), palladium acetate (33 mg, 0.15 mmol), tri-ortho-tolylphosphine (180 mg, 0.59 mmol) in triethylamine (20 ml) under an atmosphere of nitrogen was stirred at 100 °C

30 for 18 h in an ampoule. The cooled reaction mixture was diluted with toluene (100 ml)

and the solid filtered off. The organic phase was washed with water (3 x 60 ml), dried (MgSO₄), filtered and evaporated in vacuo affording 5.69 g of a solid which was suspended in a mixture of heptane (80 ml) and diethyl ether (15 ml) and stirred for 18 h at room temperature. The solid was filtered off and washed with heptane and with a
5 mixture of heptane and diethyl ether (95:5), dried in vacuo at 50 °C for 3 h affording 4.53 g (80 %) of 3-(3-(biphenyl-4-yloxymethyl)phenyl)acrylic acid tert-butyl ester as a solid.

TLC: R_f = 0.52 (SiO₂: ethyl acetate/heptane = 1:4)

10 ¹H NMR (200 MHz, CDCl₃) δ_H 1.55 (s, 9H), 5.12 (s, 2H), 6.41 (d, 1H, J_H = 14.6 Hz), 7.05 (m, 2H), 7.31 - 7.66 (m, 12H).

To a solution of the above tert-butyl ester (4.0 g, 10.35 mmol) in dichloromethane (50 ml) was added trifluoroacetic acid (5 ml) and the reaction mixture was stirred for 5 h at
15 room temperature. An additional 5 ml of trifluoroacetic acid was added and the reaction mixture was stirred for 60 h at room temperature. The precipitate was filtered off and washed with dichloromethane (2 x 20 ml), diethyl ether (2 x 20 ml) and dried in vacuo at 50 °C for 10 h affording 2.78 g (81 %) of the title compound as a solid.

20 Calculated for C₂₂H₁₈O₃:

C, 79.98 %; H, 5.49 %. Found:


C, 80.44 %; H, 5.59 %.

HPLC retention time = 31.80 minutes. (water/acetonitrile 1:1, 0.01 N (NH₄)₂SO₄ buffer, pH = 2.5)

25 ¹H NMR (200 MHz, DMSO-d₆): δ_H 5.17 (s, 2H), 6.57 (d, 1H, J_H = 16.02 Hz), 7.11 (m, 2H), 7.26 - 7.68 (m, 11H), 7.79 (s, 1H), 12.46 (bs, 1H).

EXAMPLE 2

30 3-(2-(4-Phenyl-piperazin-1-ylmethyl)-phenyl)acrylic acid



2-Bromobenzyl bromide (10.20 g, 0.04 mol) was dissolved in dry N,N-dimethylformamide (100 ml), 1-phenylpiperazine (6.83 g, 0.04 mol) and potassium carbonate (16.59 g, 0.12 mol) were added. The mixture was stirred at room temperature for 24 h. The mixture was poured into water (250 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic extracts were washed with water (3 x 50 ml), brine (50 ml), dried (MgSO₄) and evaporated in vacuo. The solid remainder was washed with heptane and filtered off and dried in vacuo affording 13.1 g (99 %) of 1-(2-(2-bromo-benzyl)-4-phenyl-piperazine as a solid.

TLC: R_f = 0.48 (Ethyl acetate/heptane = 1:4)

A mixture of the above piperazine (4.88 g, 14.7 mmol), tert-butyl acrylate (2.80 ml, 19.1 mmol), palladium acetate (33 mg, 0.15 mmol), tri-ortho-tolyl phosphine (180 mg, 0.59 mmol) in triethylamine (20 ml) under an atmosphere of nitrogen was stirred at 100 °C for 24 h in an ampoule. The cooled reaction mixture was diluted with toluene (150 ml) and the solid filtered off. The organic phase was washed with water (3 x 60 ml), brine (50 ml), dried (MgSO₄), filtered and evaporated in vacuo affording a solid which was suspended in heptane (80 ml) and stirred at room temperature. The solid was filtered off and washed with heptane, dried in vacuo at 50 °C for 3 h affording 1.18 g (26 %) of 3-(2-(4-phenyl-piperazin-1-ylmethyl)-phenyl)acrylic acid tert-butyl ester as a solid. By cooling the heptane phase an additional 3.4 g (74 %) of 3-(2-(4-phenyl-piperazin-1-ylmethyl)-phenyl)acrylic acid tert-butyl ester was obtained.

25

TLC: R_f = 0.33 (SiO₂: ethyl acetate/heptane = 1:4)

¹H NMR (200 MHz, CDCl₃): δ_H 1.53 (s, 9H), 2.62 (m, 4H), 3.17 (m, 4H), 3.65 (s, 2H), 6.30 (d, 1H, J_H = 16.01 Hz), 6.87 (m, 3H), 7.28 (m, 5H), 7.59 (m, 1H), 8.15 (d, 1H, J_H = 16.01 Hz).

To a solution of the above tert-butyl ester (3.35 g, 10.7 mmol) in dichloromethane (35 ml) was added trifluoroacetic acid (6.0 ml) and the reaction mixture was stirred for 20 h at room temperature. An additional 6 ml of trifluoroacetic acid was added and the
5 reaction mixture was stirred for an additional 24 h at room temperature. The volatiles were evaporated in vacuo and the remainder was dissolved in 0.1 N hydrochloric acid (100 ml) and stirred for 24 h. The precipitate was filtered off and washed with water (3 x 20 ml), dried in vacuo at 50°C and recrystallised from ethyl acetate affording 1.06 g (27 %) of the title compound as a solid.

10


HPLC retention time = 20.77 minutes. (water/acetonitrile 8:2, 0.01 N (NH₄)₂SO₄ buffer, pH = 2.5)

¹H NMR (200 MHz, DMSO-d₆): δ, 2.75 - 3.90 (m, 8H), 4.55 (bs, 2H), 6.58 (d, 1H), 6.85 (t, 1H), 6.99 (d, 2H), 7.27 (t, 2H), 7.48 - 7.66 (m, 3H), 7.89 (m, 1H), 8.05 (d, 1H).

15

EXAMPLE 3

3-(1-Biphenyl-4-ylmethyl-1H-indol-3-yl)acrylic acid



20

To a solution of 3-(indol-3-yl)acrylic acid ethyl ester (2.2 g, 10 mmol) in N,N-dimethylformamide (40 ml) was added sodium hydride (440 mg, 11 mmol, 60 % in mineral oil). After stirring at room temperature for 1 h 4-phenyl-benzylchloride
25 (2.28 g, 11 mmol) and potassium iodide (170 mg, 1 mmol) were added. The resulting reaction mixture was stirred at room temperature for 4 h and poured on to ice water (400 ml). The precipitate was filtered off and washed with water (2 x 50 ml) and dried in vacuo at 50 °C for 18 h. The crude product was washed with

heptane, filtered off and dried in vacuo at 50 °C affording 3.75 g of an solid which was recrystallised from acetonitrile (50 ml) affording 3.25 g (85 %) of 3-(1-biphenyl-4-ylmethyl-1H-indol-3-yl)acrylic acid ethyl ester as a solid.

To a mixture of the above indol acrylic acid ethyl ester (3.25 g, 8.5 mmol), ethanol (25 ml), water (25 ml), and tetrahydrofuran (25 ml) was added sodium hydroxide (1.03 g, 26 mmol) and the mixture was stirred at 50 °C for 24 h. Water (250 ml) was added and the reaction mixture was extracted with diethyl ether (2 x 100 ml). pH of the aqueous phase was adjusted to pH = 2 with 5N hydrochloric acid and the precipitate was filtered off, washed with water (3 x 15 ml) and dried in vacuo at 50 °C affording 2.87 g (96 %) of the title compound as a solid.

Calculated for $C_{24}H_{19}NO_2$:


C, 81.56 %; H, 5.42 %; N, 3.96%. Found:

C, 81.47 %; H, 5.61 %; N, 3.70%.

15

EXAMPLE 4

3-(1-Biphenyl-4-ylmethyl-1H-imidazol-4-yl)acrylic acid



20

To a solution of urocanic acid (25 g, 0.181 mol) in methanol (300 ml) was slowly added concentrated sulphuric acid (11.2 ml, 0.199 mol) and the reaction mixture was stirred at reflux temperature for 19 h. The reaction mixture was cooled and the volatiles were evaporated in vacuo. The resulting solid was stirred for 1 h with a mixture of diethyl ether and methanol (9:1) (200 ml). The remaining solid was filtered off, washed with acetone (80 ml), diethyl ether (100 ml) and dried in vacuo at 50 °C for 48 h which afforded 46.7 g (100 %) of urocanic acid methyl ester dihydrogen sulphate.

- To a suspension of potassium carbonate (25.5 g, 184 mmol) in dry N,N-dimethylformamide (200 ml) was added the above methyl ester (11.52 g, 46.05 mmol) and the mixture was stirred for 1 h at room temperature. 4-
- 5 (Chloromethyl)biphenyl (10.0 g, 48.4 mmol) and potassium iodide (100 mg) was added and the reaction mixture was stirred at 45 °C for 18 h under an atmosphere of dry nitrogen. The cooled reaction mixture was poured into a mixture of ice water (400 ml) and saturated aqueous ammonium chloride (100 ml) and extracted with ethyl acetate (3 x 200 ml). The combined organic extracts were washed with water
- 10 (3 x 150 ml), dried (MgSO₄) and evaporated in vacuo which afforded a solid which was washed with diethyl ether (100 ml) filtered off and air dried. Recrystallisation from isopropanol (50 ml) afforded after drying in vacuo at 50 °C 11.2 g (76 %) of 3-(1-biphenyl-4-ylmethyl-1H-imidazol-4-yl)acrylic acid methyl ester as a solid.
- 15 To a solution of the above methyl ester (2.0 g, 6.28 mmol) in a mixture of ethanol (10 ml), tetrahydrofuran (15 ml) and water (10 ml) was added sodium hydroxide (377 mg, 9.4 mmol) and the resulting mixture was stirred at room temperature for 22 h. The precipitate was filtered off and washed with a mixture of ethanol and tetrahydrofuran (1:2) followed by diethyl ether and dried in vacuo at 50 °C which
- 20 afforded 1.29 g (63 %) of the title compound as the sodium salt.

Calculated for C₁₉H₁₅NaN₂O₂, 1.75 H₂O:

C, 63.77 %; H, 5.21 %; N, 7.83 %. Found:

C, 63.55 %; H, 5.21 %; N, 7.73.

25


HPLC retention time = 4.16 minutes. (water/acetonitrile 1:1, 0.01 N (NH₄)₂SO₄ buffer, pH = 2.5)

¹H NMR (200 MHz, MeOH-d₄): δ_H 5.14 (s, 2H), 6.39 (d, 1H, J_H = 15.8 Hz), 7.12 - 7.35 (m, 7H), 7.49 - 7.55 (m, 4H), 7.64 (d, 1H).

30

EXAMPLE 5

3-(3-(2-(4-Quinolin-2-yl-piperazin-1-yl)ethyl)phenyl)acrylic acid hydrochloride



A mixture of 2-chloroquinoline (10.0 g, 60.5 mmol), piperazine (26.1 g, 303 mmol) and pyridine (15 ml) was heated reflux temperature for 4 h. The hot reaction mixture was poured into a conical flask and diluted with tetrahydrofuran (150 ml). The precipitated solid was filtered off and washed with diethyl ether (3 x 50 ml) and the combined organic phases were evaporated in vacuo. The residue was suspended in a mixture of diethyl ether (200 ml) and 96 % ethanol (80 ml) and undissolved solid was filtered off and washed with diethyl ether. The organic phase was evaporated in vacuo affording a solid which was crushed under water (200 ml) filtered off and washed with water (3 x 50 ml), diethyl ether (3 x 40 ml), dried in vacuo at 50 °C affording 11.8 g (92 %) of 2-(1-piperazinyl)quinoline as a solid.

A mixture of the above quinoline (7.0 g, 32.8 mmol), 2-bromo-1-(3-bromophenyl)ethanone (9.12 g, 32.82 mmol), potassium carbonate (13.61 g, 98.46 mmol) and methyl ethyl ketone (150 ml) was heated at 80 °C for 18 h. The cooled reaction mixture was poured into water (250 ml) and extracted with ethyl acetate (150 ml). The organic phase was washed with 10 % aqueous sodium chloride (3 x 150 ml), dried (MgSO₄), filtered and evaporated in vacuo affording a syrup which was crystallised from a mixture of heptane (200 ml) and diethyl ether (50 ml) affording, after drying in vacuo at 50 °C, 10.8 g (80 %) of 1-(3-bromophenyl)-2-(4-quinolin-2-yl-piperazin-1-yl)ethanone as a solid.

To a mixture of the above ethanone (4.0 g, 9.75 mmol), potassium hydroxide (1.86 g, 33.15 mmol, powder) and diethyleneglycol (60 ml) under an atmosphere of nitrogen was added hydrazine hydrate (1.2 ml, 22.4 mmol). The resulting reaction mixture was heated at 110 °C for 2 h with a condenser attached to the reaction flask followed by 1 h without condenser. The temperature was raised to 140 °C for

1 h and finally to 190 °C for 15 min. The resulting reaction mixture was allowed to cool to room temperature and stirred at this temperature for 18 h. Water (20 ml) was added and the precipitate was filtered off, washed with water (4 x 100 ml), heptane (3 x 15 ml) and dried in vacuo at 50 °C which afforded 2.22 g (58 %) of 2-(4-(2-(3-bromophenyl)ethyl)piperazin-1-yl)quinoline as a solid.

A mixture of the above piperazine (2.0 g, 5.05 mmol), tert-butyl acrylate (1.05 ml, 6.56 mmol), palladium acetate (12 mg, 0.051 mmol), tri-ortho-tolyl phosphine (62 mg, 0.202 mmol) in triethylamine (10 ml) under an atmosphere of nitrogen was stirred at 100 °C for 24 h in a screw cap ampoule. The cooled reaction mixture was diluted with ethyl acetate (50 ml) and the solid filtered off and washed with ethyl acetate (25 ml). The combined organic phases were washed with water (3 x 80 ml), dried (MgSO₄), filtered and evaporated in vacuo. The residue was purified by column chromatography on silicagel (400 ml) using a mixture of ethyl acetate and heptane (1:1) as eluent affording a syrup which was crystallised from heptane (20 ml). The solid was filtered off and washed with heptane, dried in vacuo at 50 °C affording 1.51 g (67 %) of 3-(3-(2-(4-quinolin-2-yl-piperazin-1-yl)ethyl)phenyl)acrylic acid tert-butyl ester as a solid.

To a mixture of the above tert-butyl ester (1.0 g, 2.25 mmol) in dichloromethane (10 ml) was added trifluoroacetic acid (2.5 ml) and the mixture was stirred for 18 h at room temperature. The reaction mixture was evaporated in vacuo, the residue was dissolved in isopropanol (20 ml) and evaporated in vacuo (repeated two times). The remaining syrup was dissolved in diethyl acetate (50 ml). 1N sodium hydroxide was added until pH = 8 and the precipitate was filtered off washed with water, diethyl ether and ethyl acetate, dried in vacuo at 50 °C affording 790 mg (93 %) of the title compound as the free acid. To 500 mg of the free acid dissolved in tetrahydrofuran (10 ml) was added 1N hydrochloric acid (20 ml) and the resulting mixture was stirred at room temperature for 18 h. The precipitate was filtered off, washed with tetrahydrofuran (10 ml), isopropanol (10 ml) and diethyl ether (10 ml), dried in vacuo at 50 °C for 18 h affording 350 mg (63 %) of the title compound as a solid.

Calculated for $C_{24}H_{25}N_3O_2 \cdot 1HCl, 3H_2O$:


C, 60.31 %; H, 6.75 %; N, 8.79. Found:

C, 60.09 %; H, 6.64 %; N, 8.63.

- 5 HPLC retention time = 4.27 minutes. (water/acetonitrile 7:3, 0.01 N $(NH_4)_2SO_4$ buffer, pH = 2.5).

EXAMPLE 6

- 10 3-(5-Oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-yl)acrylic acid



- 15 A mixture of phthalic acid anhydride (43 g, 0.291 mol), 3-bromophenyl acetic acid (62.5 g, 0.291 mol) and sodium acetate (2 g, 0.015 mol) was heated at 220 °C for 2 h under an atmosphere of nitrogen. The reaction mixture was cooled to about 80 °C and ethanol (75 ml) was added. The precipitate was filtered off, washed with a mixture of heptane and ethanol (9:1) and dried in vacuo at 50 °C which afforded 71 g (81 %) of 3-(3-bromobenzylidene)-3H-isobenzofuran-1-one as a solid.

20

- A mixture of the above isobenzofuran (71 g, 0.236 mol), red phosphorus (29.2, 0.943 mol) and 57 % aqueous hydrogen iodide (400 ml) was heated at reflux for 18 h. The cooled reaction mixture was poured onto ice water (1.5 l) and pH was made alkaline with 50 % aqueous sodium hydroxide. The resulting mixture was
25 extracted with diethyl ether (2 x 250 ml). pH of the aqueous phase was adjusted to pH = 1 with concentrated hydrochloric acid. The precipitate was filtered off, washed with water and heptane, dried in vacuo at 50 °C which afforded 46.6 g (65 %) of 2-(2-(3-bromophenyl)ethyl)benzoic acid as a solid.

- 30 To a solution of aluminium chloride (48.9 g, 0.366 mol) in dichloro-methane (250 ml) was added dropwise a solution of 2-(2-(3-bromophenyl)ethyl)benzoyl chloride

(50 g, 0.153 mol) in dichloromethane (200 ml) at room temperature. The reaction mixture was stirred for 2 h at room temperature and poured onto ice water (750 ml). The organic phase was separated, dried (MgSO_4), filtered and evaporated in vacuo which afforded 43.3 g (99 %) of 2-bromo-10,11-dihydro-5H-

5 dibenzo[a,d]cycloheptan-5-one as a solid.

A mixture of 2-bromo-10,11-dihydro-5H-dibenzo[a,d]cycloheptan-5-one (2.0 g, 6.96 mmol), tert-butyl acrylate (1.2 g, 9.05 mmol), palladium acetate (16 mg, 0.07 mmol), tri-*o*-tolylphosphine (85 mg, 0.290 mmol), triethylamine (10 ml) in N,N-
10 dimethylformamide (50 ml) was heated at 100 °C for 18 h under an atmosphere of nitrogen. The cooled reaction mixture was diluted with water (100 ml), extracted with diethyl ether (2 x 100 ml). The combined organic extracts were washed with saturated aqueous ammonium chloride (2 x 100 ml), dried (MgSO_4), filtered and evaporated in vacuo. The residue (1.8 g) was purified by column chromatography
15 on silicagel (600 ml) using a mixture of ethyl acetate and heptane (1:10) as eluent affording 0.7 g (30 %) of 3-(5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-yl)acrylic acid tert-butyl ester as an oil.

To a mixture of the above tert-butyl ester (0.7 g, 2.09 mmol) in dichloromethane
20 (40 ml) was added trifluoroacetic acid (2.5 ml) and the mixture was stirred for 18 h at room temperature. An additional 0.5 ml of trifluoroacetic acid was added and the reaction mixture was stirred for an additional 18 h at room temperature. The reaction mixture was washed with water (50 ml), dried (MgSO_4), filtered and evaporated in vacuo affording an solid which was dried in vacuo at 50 °C for 18 h.
25 This afforded 0.12 g (21 %) of the title compound as a solid.

Calculated for $\text{C}_{18}\text{H}_{14}\text{O}_3$:

C, 76.94 %; H, 5.13 %. Found:

C, 76.89 %; H, 5.08 %.


30

m.p.: 234-236 °C

HPLC retention time = 10.0 minutes. (water/acetonitrile 1:1, 0.01 N $(\text{NH}_4)_2\text{SO}_4$ buffer, pH = 2.5).

EXAMPLE 7

3-(2,3-Dihydro-benzo[b]furan-5-yl)acrylic acid



A mixture of 5-bromo-2,3-dihydro-benzo[b]furan (9.95 g, 0.05 mol), tert-butyl acrylate (9.71 g, 0.075 mol), palladium tetrakis(triphenylphosphine) (200 mg, 0.2 mmol), triethylamine (11 ml) in N,N-dimethylformamide (40 ml) was heated at reflux temperature for 20 h under an atmosphere of nitrogen. The cooled reaction mixture was diluted with water (150 ml) and extracted with ethyl acetate (2 x 50 ml). The combined organic extracts were washed with water (50 ml), saturated aqueous ammonium chloride (20 ml), dried (MgSO₄), filtered and evaporated in vacuo. The residue was recrystallised from heptane affording after drying 1.55 g (13 %) of 3-(2,3-dihydro-benzo[b]furan-5-yl)acrylic acid tert butyl ester as a solid.

To a solution of the above tert butyl ester (1.23 g, 5 mmol) in dichloromethane (10 ml) was added trifluoroacetic acid (2.5 ml) and the reaction mixture was stirred at room temperature for 20 h. The volatiles were evaporated in vacuo, the residue was dissolved in toluene (20 ml) and evaporated in vacuo (repeated three times) affording a crude product. The crude product was purified by column chromatography on silicagel (180 ml) using a mixture of ethyl acetate, heptane and formic acid (45:45:10) as eluent. This afforded 0.37 g which was recrystallised from ethyl acetate affording 0.16 g (16 %) of the title compound as a solid.

Calculated for C₁₁H₁₀O₃:

C, 69.46 %; H, 5.30 %. Found:

C, 69.32 %; H, 5.45 %.


30

HPLC retention time = 4.4 minutes. (water/acetonitrile 1:1, 0.01 N (NH₄)₂SO₄ buffer, pH = 2.5).

EXAMPLE 8

3-(9-Biphenyl-4-ylmethyl-9H-carbazol-3-yl)acrylic acid

5



To a solution of 3-bromo-9H-carbazole (7.38 g, 30 mmol, prepared as described in Tetrahedron (1992), 48, 4779) in N,N-dimethylformamide (200 ml) was added
10 portion wise sodium hydride (1.6 g, 39 mmol, 60 % in mineral oil) during 15 min. After stirring at room temperature for 1 h, 4-phenyl-benzylchloride (6.21 g, 30 mmol) was added portion wise during 10 min. The resulting reaction mixture was stirred at room temperature for 20 h poured onto water (300 ml) and stirred for 4 h. The precipitate was filtered off, washed with water (3 x 150 ml) and dried in vacuo
15 at 50 °C for 18 h. The crude product was washed with heptane, filtered off and dried in vacuo at 50 °C affording 12 g (100 %) of 9-(biphenyl-4-ylmethyl)-3-bromo-9H-carbazole as a solid.

A mixture of the above bromo-carbazole (7.15 g, 18 mmol), tert-butyl acrylate (3.01
20 g, 23.3 mmol), palladium acetate (40 mg, 0.2 mmol), tri-*o*-tolylphosphine (220 mg, 0.7 mmol) and triethylamine (10 ml) in an screw cap ampoule was heated at 100 °C for 20 h. The cooled reaction mixture was diluted with ethyl acetate (75 ml), washed with water (3 x 20 ml), dried (MgSO₄), filtered and evaporated in vacuo. The residue (9.6 g) was purified by column chromatography on silicagel (600 ml)
25 using toluene as eluent which afforded 4.92 g (60 %) of 3-(9-(biphenyl-4-ylmethyl)-9H-carbazol-3-yl)acrylic acid tert-butyl ester as a solid.

To a solution of the above tert-butyl ester (1.38 g, 3 mmol) in dioxane (15 ml) was added lithium hydroxide hydrate (640 mg, 15 mmol) and water (15 ml) the reaction
30 mixture was stirred at reflux temperature for 24 h. The cooled reaction mixture was diluted with water (50 ml) and acidified with 5N hydrochloric acid to pH = 1. The

precipitate was filtered off and washed with water (3 x 15 ml), diethyl ether (3 x 15 ml) and dried in vacuo. The crude product was suspended in a mixture of diethyl ether (30 ml) and tetrahydrofuran (15 ml) and stirred at room temperature for 68 h. The precipitate was filtered off and washed with diethyl ether and dried in vacuo
5 affording 0.89 g (74 %) of the title compound as a solid.

Calculated for $C_{26}H_{21}NO_2$:

C, 83.35 %; H, 5.25 %; N, 3.47 %. Found:

C, 83.24 %; H, 5.25 %; N, 3.24 %.


10

m.p.: 257-257.5 °C

HPLC retention time = 11.7 minutes. (water/acetonitrile 3:7, 0.01 N $(NH_4)_2SO_4$ buffer, pH = 2.5).

15 EXAMPLE 9

3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-2-yl)acrylic acid



20

A mixture of 2-bromo-10,11-Dihydro-5H-dibenzo[b,f]azepin (4.11 g, 15 mmol, prepared as described in Tetrahedron (1992), **48**, 4779) tert-butyl acrylate (2.91 g, 22.5 mmol), palladium acetate (40 mg, 0.2 mmol), tri-*o*-tolylphosphine (183 mg, 0.6 mmol) and triethylamine (20 ml) in an screw cap ampoule was heated at 100 °C for
25 20 h. The cooled reaction mixture was diluted with ethyl acetate (50 ml), washed with water (3 x 20 ml), dried ($MgSO_4$), filtered and evaporated in vacuo. The residue (3.9 g) was purified by column chromatography on silicagel (600 ml) using a mixture of ethyl acetate and heptane (1:6) as eluent which afforded 1.62 g (34 %) of 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-2-yl)acrylic acid tert-butyl ester as a
30 solid.

To a solution of the above tert-butyl ester (600 mg, 1.9 mmol) in dioxane (15 ml) was added lithium hydroxide hydrate (400 mg, 9.3 mmol) and water (15 ml) the reaction mixture was stirred at reflux temperature for 16 h. The cooled reaction mixture was decanted and diluted with water (60 ml). Acidified with 5N
5 hydrochloric acid to pH = 1. The precipitate was filtered off, washed with water (3 x 15 ml) and dried in vacuo affording 409 mg (82 %) of the title compound as a solid.

Calculated for $C_{17}H_{14}NO_2$:

C, 77.25 %; H, 5.34 %; N, 5.30 %. Found:

10 C, 76.98 %; H, 5.86 %; N, 5.09 %.

m.p.: 215-216 °C

1H NMR (200 MHz, DMSO- d_6): δ_H 2.98 (s, 4H), 6.28 (d, 1H, J_H = 15.7 Hz), 6.74 (dt,
15 1H), 7.04 (m, 4H), 7.38 (m, 2H), 7.46 (d, 1H, J_H = 15.7), 8.74 (1H, s, NH), 12.05 (bs, 1H).

HPLC retention time = 10.76 minutes. (water/acetonitrile 1:1, 0.01 N $(NH_4)_2SO_4$ buffer, pH = 2.5)

20

EXAMPLE 10

The PTP1B and PTP α cDNA was obtained by standard polymerase chain reaction technique using the Gene Amp Kit according to the manufacturer's instructions (Perkin
25 Elmer/Cetus). The oligonucleotide primers were designed according to published sequences (Chernoff *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 87: 2735-2739 (1990); Krueger *et al.*, *EMBO J.* 9: 3241-3252 (1990)) including convenient restriction nuclease sites to allow cloning into expression vectors. The cDNA corresponding to the full-length sequence of PTP1B and the intracellular part of PTP α were introduced into the
30 insect cell expression vector pVL1392. The proteins were expressed according to standard procedures. PTP1B was semi-purified by ion exchange chromatography, and PTP α was purified to apparent homogeneity using a combination of ion exchange chromatography and gel filtration techniques using standard procedures. TC-PTP and LAR domain 1 were obtained from New England Biolabs. *Yersinia* PTP was a kind gift

from J.E. Dixon, The University of Michigan, Ann Arbor, U.S.A. p-Nitrophenyl phosphate was purchased from Sigma and used without further purification.

5 *Methods*

p-Nitrophenyl phosphate (pNPP) is a general phosphatase substrate including a substrate for PTPases. When pNPP (colorless) is hydrolyzed by a phosphatase to phosphate and p-nitrophenolate (yellow in alkaline solutions) the enzyme reaction can
10 be followed by measuring the optical density at 410 nm after adjusting the pH appropriately. pNPP was used as general substrate to analyze the PTPase inhibitory capacity of the compounds of the invention.

The inhibiting effect of a compound is given by its K_i value, which expresses the
15 concentration of inhibitor (μM) in the reaction mixture necessary for a 50 percent reduction of the enzyme activity.

The K_i may be determined by a titration curve using several appropriately diluted solutions of the inhibitor or by using the following more simple formula, when the
20 concentration of inhibitor is in large excess of the enzyme concentration:

$$K_i = I_o \times E / (E_o - E)$$

where I_o is the concentration of inhibitor (μM) added to the reaction mixture, E is the
25 activity of the enzyme in the reaction mixture containing the inhibitor, and E_o is the enzyme activity in a corresponding control reaction mixture without the inhibitor.

The K_i values of inhibitors towards PTP1B were measured as follows. In all cases the inhibiting effects were determined at pH 5.5 and at 37 °C with a reaction time of 60
30 minutes.

The reaction mixtures were:

- 1) 25 μ l enzyme solution
25 μ l inhibitor solution in DMSO
500 μ l substrate solution

5 or

- 2) 25 μ l enzyme solution
25 μ l DMSO
500 μ l substrate solution

10

The substrate solution contained 0.2 M acetate buffer, pH 5.5, 11 mM p-nitrophenyl phosphate, 5.5 mM dithiotreitol.

- The reaction was stopped by addition of 4 ml 0.2 N NaOH, and the enzyme activity
- 15 was determined by measuring the release of p-nitrophenol at 410 nm. The inhibiting effect was calculated as shown above.

- The K_i values of inhibitors towards TC-PTP, LAR domain1, PTP α domain 1+2, and
- Yersinia* PTP were measured essentially as described for PTP1B with the exception
- 20 that all reactions were carried out in 96-wells microtiter plates. In all cases the inhibiting effects were determined at pH 5.5 and at room temperature with a reaction time of 15 minutes.

The reaction mixtures were:

- 25 1) 5 μ l enzyme solution
5 μ l inhibitor solution in DMSO (final concentration 100 μ M)
90 μ l substrate solution

or

- 30 2) 5 μ l enzyme solution
5 μ l DMSO
90 μ l substrate solution

The final concentrations: 0.2 M acetate buffer, pH 5.5, 5 mM p-nitrophenyl phosphate,

5 mM dithiotreitol.


The reaction was stopped by addition of 100 μ l 0.4 N NaOH, and the enzyme activity was determined by measuring the release of p-nitrophenol at 405 nm. The inhibiting
5 effect was calculated as shown above.

Results

- 10 Using the above assay systems we have demonstrated that compounds of the invention are PTPase inhibitors.

CLAIMS

1. A compound of formula (I)



wherein

10 n is 1, 2, 3, 4, or 5 and (L)_n represents up to five (5) substituents which independently of each other are hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, hydroxy, halogen, trihalogenomethyl, hydroxy-C₁₋₆-alkyl, amino-C₁₋₆-alkyl, COR₂, NO₂, CN, CHO, C₁₋₆-alkanoyloxy, carbamoyl, NR₅R₆, aryloxy optionally substituted;

15 R₂ is C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted, OH, NR₃R₄ wherein R₃ and R₄ independently of each other are hydrogen, C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted;

R₅ and R₆ are independently of each other hydrogen or C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted or COZ₁ wherein Z₁ is C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted;

20

L is A-Y₁-(W₁)-X-(W₂)-Y₂ wherein X is a chemical bond, CO, CONR₇, NR₇CO, NR₇, O, S, SO, or SO₂;

25 Y₁ and Y₂ are independently a chemical bond, O, S, or NR₇;
R₇ is hydrogen, C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted, COZ₂ wherein Z₂ is C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted;

30 W₁ and W₂ are independently a chemical bond or saturated or unsaturated C₁₋₆-alkylene;

A is aryl optionally substituted, heteroaryl optionally substituted, biaryl optionally

substituted, arylheteroaryl optionally substituted, NR_8R_9 wherein R_8 and R_9 independently are hydrogen, C_{1-6} -alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted, COZ_3 wherein Z_3 is C_{1-6} -alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted

5 or

when R_8 and R_9 together with the nitrogen atom forms a ring system A is a saturated or partially saturated heterocyclic ring system optionally substituted with C_{1-6} -alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted, OH, C_{1-6} -alkoxy, hydroxy- C_{1-6} -alkyl, amino- C_{1-6} -alkyl, COZ_4 wherein Z_4 is OH, C_{1-6} -alkyl,

- 10 $\text{NR}_{10}\text{R}_{11}$ wherein R_{10} and R_{11} independently are hydrogen, C_{1-6} -alkyl; R_1 is hydrogen, C_{1-6} -alkyl, aryl optionally substituted, aralkyl optionally substituted; and Ar_1 is aryl or heteroaryl;

or a pharmaceutically acceptable salt thereof.

15

2. A compound according to the preceding claim

wherein

L is $\text{A-Y}_1\text{-(W}_1\text{)-X-(W}_2\text{)-Y}_2$ wherein X is a chemical bond, CO, CONR_7 , NR_7CO , NR_7 , O, S, SO, or SO_2 ;

- 20 Y_1 and Y_2 are independently a chemical bond, O, S, or NR_7 ;
 R_7 is hydrogen, C_{1-6} -alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted, COZ_2 wherein Z_2 is C_{1-6} -alkyl, aryl optionally substituted, aralkyl optionally substituted;
- 25 W_1 and W_2 are independently a chemical bond or saturated or unsaturated C_{1-6} -alkylene;

A is aryl optionally substituted, heteroaryl optionally substituted, biaryl optionally substituted, arylheteroaryl optionally substituted, NR_8R_9 wherein R_8 and R_9

- 30 independently are hydrogen, C_{1-6} -alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted, COZ_3 wherein Z_3 is C_{1-6} -alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted or
 when R_8 and R_9 together with the nitrogen atom forms a ring system A is a saturated

or partially saturated heterocyclic ring system optionally substituted with C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted, heteroaryl optionally substituted, OH, C₁₋₆-alkoxy, hydroxy-C₁₋₆-alkyl, amino-C₁₋₆-alkyl, COZ₄ wherein Z₄ is OH, C₁₋₆-alkyl, NR₁₀R₁₁ wherein R₁₀ and R₁₁ independently are hydrogen, C₁₋₆-alkyl;

5

R₁ is hydrogen, C₁₋₆-alkyl, aryl optionally substituted, aralkyl optionally substituted;

and Ar₁ is aryl or heteroaryl;

and n is preferably 1, 2 or 3.

10

3. A compound according to any one of the preceding claims wherein R₁ is hydrogen.

4. A compound according to any one of the preceding claims wherein the

15 cinnamic acid double bond conformation is trans (E).

5. A compound according to any one of the preceding claims wherein Ar₁ is an optionally substituted phenyl or heteroaryl.

20 6. A compound according to any one of the preceding claims wherein Ar₁ is an optionally substituted phenyl.

7. A compound according to any one of the preceding claims wherein Ar₁ is an optionally substituted heteroaryl.

25 8. A compound according to any one of the preceding claims selected from the following:

3-(3-(Biphenyl-4-yloxymethyl)phenyl)acrylic acid;

3-(2-(4-Phenyl-piperazin-1-ylmethyl)phenyl)acrylic acid, or the dihydrochloride salt thereof;

30 3-(1-Biphenyl-4-ylmethyl-1H-indol-3-yl)acrylic acid;

3-(1-Biphenyl-4-ylmethyl-1H-imidazol-4-yl)acrylic acid;

3-(3-(2-(4-Quinolin-2-yl-piperazin-1-yl)ethyl)phenyl)acrylic acid, or the hydrochloride salt thereof;


3-(5-Oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-yl)acrylic acid;

3-(2,3-Dihydro-benzo[b]furan-5-yl)acrylic acid;


3-(9-Biphenyl-4-ylmethyl-9H-carbazol-3-yl)acrylic acid; or

3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-2-yl)acrylic acid.

- 5 9. A method of preparing a compound according to any one of the preceding compound claims, **characterized in**



- allowing a compound of formula (II), wherein $(L)_n$, n , and Ar_1 are as defined in claim 1
10 and X_1 is a suitable leaving group to react with a compound of formula (III) wherein R_1 is as defined in claim 1, in order to obtain the compound of formula (I); or



- allowing a compound of formula (IV), wherein $(L)_n$, n , and Ar_1 are as defined above to
15 react with a compound of formula (V) wherein R_1 is as defined above and L_w is trimethylsilyl, diethylphosphat or carbonyloxy C_{1-6} -alkyl, in order to obtain the compound of formula (I).

10. A pharmaceutical composition comprising as active component a compound
20 according to any one of the preceding compound claims together with a pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition suitable for modulating the activity of PTPases or other molecules with tyrosine phosphate recognition unit(s) comprising an effective amount of a compound according to any one of the preceding compound claims
25 together with a pharmaceutically acceptable carrier or diluent.

12. The pharmaceutical composition according to any one of claims 10 or 11 suitable for treating or preventing type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity
30 and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with

decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

5

13. The pharmaceutical composition according to any one of the claims 10, 11 or 12 comprising between 0.5 mg and 1000 mg of a compound according to any one of the preceding compound claims per unit dose.

10 14. A method of modulating the activity of PTPases or other molecules with phosphotyrosine recognition unit(s) in a subject in need of such treatment comprising administering to said subject an effective amount of a compound or composition according to any one of the preceding compound or composition claims.

15 15. The use of a compound according to any one of the preceding compound claims for preparing a medicament.

16. The use of a compound according to any one of the preceding compound claims for preparing a medicament for modulating the activity of PTPases or other
20 molecules with tyrosine phosphate recognition unit(s).

17. The use of a compound according to any one of the preceding compound claims for preparing a medicament for treating or preventing type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions
25 including autoimmunity and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain
30 including Alzheimer's disease and schizophrenia, and infectious diseases.

18. The use of a compound according to any one of the preceding compound claims for preparing a medicament for treating a subject in need of such treatment.

19. The use of a compound according to any one of the preceding compound claims for preparing a medicament for use as an immunosuppressant.
20. An immobilized compound comprising a suitable solid-phase coupled with a
5 compound according to any one of the preceding compound claims.
21. A method for coupling a compound according to any one of the preceding compound claims to a suitable solid-phase matrix.
22. A method for isolating a protein or a glycoprotein with affinity for a compound
10 according to any one of the preceding compound claims from a biological sample, comprising
- contacting an immobilized compound according to claim 20 with said biological sample in order for said immobilized compound to form a complex by binding said protein or glycoprotein
 - 15 - removing unbound material from said biological sample and isolating said complex
 - extracting said protein or glycoprotein from said complex.
23. A method for isolating a protein-tyrosine phosphatase with affinity for a compound according to any one of the preceding compound claims from a biological
20 sample, comprising
- contacting an immobilized compound according to claim 20 with said biological sample in order for said immobilized compound to form a complex by binding said protein-tyrosine phosphatase
 - removing unbound material from said biological sample and isolating said complex
 - 25 - extracting said protein-tyrosine phosphatase.
24. A method for isolating a Src-homology 2 domain containing protein or a phosphotyrosine binding domain containing protein with affinity for a compound according to any one of the preceding compound claims from a biological sample,
30 comprising
- contacting an immobilized compound according to claim 20 with said biological sample in order for said immobilized compound to form a complex by binding said Src-homology 2 domain containing protein or a phosphotyrosine binding domain containing protein

- removing unbound material from said biological sample and isolating said complex
- extracting said Src-homology 2 domain containing protein or a phosphotyrosine binding domain containing protein from said complex.

5 25. A compound according to any one of the preceding compound claims coupled to a fluorescent or radioactive molecule.

26. A method for coupling a fluorescent or radioactive molecule to a compound according to any one of the preceding compound claims comprising

- 10 - contacting said compound with said fluorescent or radioactive molecule in a reaction mixture to produce a complex
- removing uncomplexed material and isolating said complex from said reaction mixture.

15 27. A method for detecting protein-tyrosine phosphatase or other molecules with phosphotyrosine recognition unit(s) in a cell or in a subject using a compound according to claim 25 comprising

- contacting said cell or an extract thereof or a biological sample from said subject or by injecting said compound into said subject in order for said compound to produce a
- 20 complex with said protein-tyrosine phosphatase or said molecules with phosphotyrosine recognition unit(s)
- detecting said complex, thereby detecting the presence of said protein tyrosine phosphatase or said other molecules with phosphotyrosine recognition unit(s).

25 28. A method for quantifying the amount of protein-tyrosine phosphatases or other molecules with phosphotyrosine recognition unit(s) in a cell or in a subject using a compound according to claim 25 comprising

- contacting said cell or an extract thereof or a biological sample from said subject or by injecting said compound into said subject in order for said compound to produce a
- 30 complex with said protein-tyrosine phosphatase or said molecules with phosphotyrosine recognition unit(s)
- measuring the amount of said complex, thereby detecting the presence of said protein tyrosine phosphatase or said molecules with phosphotyrosine recognition unit(s).

29. A method for determining the function of a given protein-tyrosine phosphatase or group of protein-tyrosine phosphatases or said molecules with phosphotyrosine recognition unit(s) in a cell or a subject using a compound according to claim 25
- 5 comprising
- contacting said cell or an extract thereof or a biological sample from said subject or by injecting said compound into said subject in order for said compound to produce a complex with said protein-tyrosine phosphatase or said molecules with phosphotyrosine recognition unit(s)
- 10 - measuring the biological effects induced by said complex.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00167

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: A61K 31/185, A61K 31/50, A61K 31/395, A61K 31/34 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CAS-ONLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF MEDICAL CHEMISTRY, Volume 22, No 7, 1979, Benjamin Blank et al, "Synthesis and Hypoglycemic Activity of Pyridyl Alcohols", page 840 - page 844, see table 1 compound 17	17
A	--	8
X	DE 2517229 A1 (BOEHRINGER MANNHEIM GMBH), 28 October 1976 (28.10.76)	17
A	--	8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "P" earlier document but published on or after the international filing date "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
12 August 1997		18 -09- 1997
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Göran Karlsson Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00167

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 2316881 A1 (BEECHAM GROUP LTD), 11 October 1973 (11.10.73)	17
A	--	8
X	GB 2205240 A (FARMITALIA CARLO ERBA S.R.L.), 7 December 1988 (07.12.88), see especially claim 6	17
A	--	8
X	ARZNEIM-FORSCH.(DRUG RES.), Volume 24, No 10, 1974, H. Sugihara et al, "Oral Hypoglycemic Agents: 1-(2-Carboxyphenyl)pyrroles" page 1560 - page 1563	17
A	--	8
X	WO 9321783 A1 (THE PENN STATE RESEARCH FOUNDATION), 11 November 1993 (11.11.93)	17
A	--	8
A	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Volume 5, No 24, 1995, Xiaodong Cao et al, "Synthesis of NH-acyl-x-aminoamides on rink resin: inhibitors of the hematopoietic protein tyrosine phosphatase" page 2953 - page 2958	8,17
A	--	
A	J.AM.CHEM.SOC., Volume 117, 1995, Edmund J. Moran et al, "Radio Frequency Tag Encoded Combinatorial Library Method for the Discovery of Tripeptide-Substituted Cinnamic Acid Inhibitors of the Protein Tyrosine Phosphatase PTP1B", page 10787 - page 10788	8,17
A,P	WO 9708934 A2 (ONTOGEN CORPORATION), 13 March 1997 (13.03.97), claim 22	8,17
	-- -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00167

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-7, 9-13 and 15-16
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 1-7 and 9-16 are too broadly formulated to permit a meaningful search, cf. Article 6. Thus, these claims include hundreds of known compounds, having therapeutic effects.
2. ☒ Claims Nos.: 14
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
A method for treatment of the human or animal body by therapy, see rule 39.1.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
8 and 17 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

The effects of the compounds given in claim 17 are so different from each other, that no technical relationship or interaction can be appreciated to be present so as to form a single inventive concept.

The application therefore contains the following inventions:

- 1) The use of compounds I for preparing a medicament for treating or preventing type I diabetes, type II diabetes, impaired glucose tolerance or insulin resistance
- 2) The use of compounds I for preparing a medicament for treating or preventing obesity
- 3) The use of compounds I for preparing a medicament for treating or preventing immune dysfunctions including autoimmunity and AIDS
- 4) The use of compounds I for preparing a medicament for treating or preventing diseases with dysfunction of the coagulation system
- 5) The use of compounds I for preparing a medicament for treating or preventing allergic diseases
- 6) The use of compounds I for preparing a medicament for treating or preventing osteoporosis
- 7) The use of compounds I for preparing a medicament for treating or preventing proliferative disorders including cancer and psoriasis
- 8) The use of compounds I for preparing a medicament for treating or preventing diseases with decreased or increased synthesis or effect of growth hormone
- 9) The use of compounds I for preparing a medicament for treating or preventing diseases of the brain including Alzheimer's disease and schizophrenia
- 10) The use of compounds I for preparing a medicament for treating or preventing infectious diseases.
- 11) An invention concerning an immobilized compound I and the use thereof according to claims 20-24
- 12) An invention concerning a compound I coupled to a fluorescent or radioactive molecule according to claims 25-29

INTERNATIONAL SEARCH REPORT
Information on patent family members

01/09/97

International application No.

PCT/DK 97/00167

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 2517229 A1	28/10/76	AR 213174 A	29/12/78
		AT 345795 B	10/10/78
		AT 349448 B	10/04/79
		AT 349451 B	10/04/79
		AU 497513 B	14/12/78
		AU 1315776 A	27/10/77
		BE 840801 A	15/10/76
		BG 26518 A	12/04/79
		CA 1047513 A	30/01/79
		CS 188280 B	28/02/79
		FR 2307528 A,B	12/11/76
		GB 1484848 A	08/09/77
		LU 74786 A	12/01/77
		NL 7603947 A	20/10/76
		SE 423231 B,C	26/04/82
		SE 7604381 A	19/10/76
		US 4113871 A	12/09/78
		US 4238506 A	09/12/80
		ZA 7602285 A	25/05/77
DE 2316881 A1	11/10/73	AR 208269 A	20/12/76
		AT 339301 B	10/10/77
		BE 797715 A	03/10/73
		BG 20352 A	05/11/75
		CA 999868 A	16/11/76
		CH 576961 A	30/06/76
		CS 183689 B	31/07/78
		FR 2182933 A,B	14/12/73
		GB 1437781 A	03/06/76
		JP 49100091 A	20/09/74
		NL 7304610 A	08/10/73
		US 4036844 A	19/07/77
		US 4053607 A	11/10/77
		ZA 7301853 A	30/01/74
GB 2205240 A	07/12/88	AU 608609 B	11/04/91
		AU 1690588 A	08/12/88
		BE 1004551 A	15/12/92
		CA 1310907 A	01/12/92
		CH 675073 A	31/08/90
		DE 3818741 A	22/12/88
		DK 298088 D	00/00/00
		FR 2616066 A	09/12/88
		JP 63310825 A	19/12/88
		NL 8801422 A	02/01/89
		SE 8802066 A	04/12/88
		US 4882347 A	21/11/89
WO 9321783 A1	11/11/93	AU 4035393 A	29/11/93
		CA 2134657 A	11/11/93
		EP 0639055 A	22/02/95
		JP 8501061 T	06/02/96
		US 5300298 A	05/04/94
WO 9708934 A2	13/03/97	AU 7735896 A	27/03/97